BIOMARKERS FOR DIAGNOSING OVARIAN CANCER

Information

  • Patent Application
  • 20220139499
  • Publication Number
    20220139499
  • Date Filed
    January 31, 2020
    4 years ago
  • Date Published
    May 05, 2022
    2 years ago
Abstract
Set forth herein are glycopeptide biomarkers useful for diagnosing diseases and conditions, such as but not limited to, cancer (e.g., ovarian), an autoimmune disease, fibrosis and aging conditions. Also set forth herein are methods of generating glycopeptide biomarkers and methods of analyzing glycopeptides using mass spectroscopy. Also set forth herein are methods of analyzing glycopeptides using machine learning algorithms.
Description
FIELD

The instant disclosure is directed to glycoproteomic biomarkers including, but not limited to, glycans, peptides, and glycopeptides, as well as to methods of using these biomarkers with mass spectroscopy and in clinical applications.


BACKGROUND

Changes in glycosylation have been described in relationship to disease states such as cancer. See, e.g., Dube, D. H.; Bertozzi, C. R. Glycans in Cancer and Inflammation—Potential for Therapeutics and Diagnostics. Nature Rev. Drug Disc. 2005, 4, 477-88, the entire contents of which are herein incorporated by reference in its entirety for all purposes. However, clinically relevant, non-invasive assays for diagnosing cancer, such as ovarian cancer, in a patient based on glycosylation changes in a sample from that patient are not yet sufficiently demonstrated.


Conventional clinical assays for diagnosing ovarian cancer, for example, include measuring the amount of the protein CA 125 (cancer antigen 125) in a patient's blood by an enzyme-linked immunosorbent assay (ELISA). However, ELISA has limited sensitivity and precision. ELISA, for example, only measures CA 125 at concentrations in the ng/mL range. This narrow measurement range limits the relevance of this assay by failing to measure biomarkers at concentrations substantially above or below this concentration range. Also, the CA 125 ELISA assay is limited with respect to the types of samples which can be assayed. As a consequence of the lack of more precise and sensitive tests, patients who might otherwise be diagnosed with ovarian cancer are not and thereby fail to receive proper follow-up medical attention.


As an alternative, mass spectroscopy (MS) offers sensitive and precise measurement of cancer-specific biomarkers including glycopeptides. See, for example, Ruhaak, L. R., et al., Protein-Specific Differential Glycosylation of Immunoglobulins in Serum of Ovarian Cancer Patients DOI: 10.1021/acs.jproteome.5b01071; J. Proteone Res., 2016, 15, 1002-1010 (2016); also Miyamoto, S., et al., Multiple Reaction Monitoring for the Quantitation of Serum Protein Glycosylation Profiles: Application to Ovarian Cancer, DOI: 10.1021/acs.jproteome.7b00541, J. Proteome Res. 2018, 17, 222-233 (2017), the entire contents of which are herein incorporated by reference in its entirety for all purposes. However, using MS to diagnose cancer, generally, or ovarian cancer specifically, has not been demonstrated to date in a clinically relevant manner.


What is needed are new biomarkers and new methods of using MS to diagnose disease states such as cancer using these biomarkers. Set forth herein in the disclosure below are such biomarkers comprising glycans, peptides, and glycopeptides, as well as fragments thereof, and methods of using the biomarkers with MS to diagnose ovarian cancer.


SUMMARY

In one embodiment, set forth herein is a glycopeptide or peptide consisting of an amino acid sequence selected from SEQ ID NOs:1-262, and combinations thereof.


In another embodiment, set forth herein is a glycopeptide or peptide consisting essentially of an amino acid sequence selected from SEQ ID NOs:1-262, and combinations thereof.


In another embodiment, set forth herein is a method for detecting one or more MRM transitions, comprising: obtaining a biological sample from a patient; digesting and/or fragmenting a glycopeptide in the sample; and detecting a multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150, described herein.


In another embodiment, set forth herein a method for identifying a classification for a sample, the method comprising: quantifying by mass spectroscopy (MS) one or more glycopeptides in a sample wherein the glycopeptides each, individually in each instance, comprises a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof; and inputting the quantification into a trained model to generate a output probability; determining if the output probability is above or below a threshold for a classification; and identifying a classification for the sample based on whether the output probability is above or below a threshold for a classification.


In yet another embodiment, set forth herein is a method for classifying a biological sample, comprising: obtaining a biological sample from a patient; digesting and/or fragmenting a glycopeptide in the sample; detecting a MRM transition selected from the group consisting of transitions 1-150; and quantifying the glycopeptides; inputting the quantification into a trained model to generate a output probability; determining if the output probability is above or below a threshold for a classification; and classifying the biological sample based on whether the output probability is above or below a threshold for a classification.


In another embodiment, set forth herein is a method for treating a patient having ovarian cancer; the method comprising: obtaining a biological sample from the patient; digesting and/or fragmenting one or more glycopeptides in the sample; and detecting and quantifying one or more multiple-reaction-monitoring (MRM) transitions selected from the group consisting of transitions 1-150; inputting the quantification into a trained model to generate an output probability; determining if the output probability is above or below a threshold for a classification; and classifying the patient based on whether the output probability is above or below a threshold for a classification, wherein the classification is selected from the group consisting of: (A) a patient in need of a chemotherapeutic agent; (B) a patient in need of a immunotherapeutic agent; (C) a patient in need of hormone therapy; (D) a patient in need of a targeted therapeutic agent; (E) a patient in need of surgery; (F) a patient in need of neoadjuvant therapy; (G) a patient in need of chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof, before surgery; (H) a patient in need of chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof, after surgery; (I) or a combination thereof; administering a therapeutically effective amount of a therapeutic agent to the patient: wherein the therapeutic agent is selected from chemotherapy if classification A or I is determined; wherein the therapeutic agent is selected from immunotherapy if classification B or I is determined; or wherein the therapeutic agent is selected from hormone therapy if classification C or I is determined; or wherein the therapeutic agent is selected from targeted therapy if classification D or I is determined wherein the therapeutic agent is selected from neoadjuvant therapy if classification F or I is determined; wherein the therapeutic agent is selected from chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof if classification G or I is determined; and wherein the therapeutic agent is selected from chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof if classification H or I is determined.


In another embodiment, set forth herein is a method for training a machine learning algorithm, comprising: providing a first data set of MRM transition signals indicative of a sample comprising a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262; providing a second data set of MRM transition signals indicative of a control sample; and comparing the first data set with the second data set using a machine learning algorithm.


In another embodiment, set forth herein is a method for diagnosing a patient having ovarian cancer; the method comprising: obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect and quantify one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262; or to detect and quantify one or more MRM transitions selected from transitions 1-150; inputting the quantification of the detected glycopeptides or the MRM transitions into a trained model to generate an output probability, determining if the output probability is above or below a threshold for a classification; and identifying a diagnostic classification for the patient based on whether the output probability is above or below a threshold for a classification; and diagnosing the patient as having ovarian cancer based on the diagnostic classification. In some examples, the method includes performing mass spectroscopy of the biological sample using MRM-MS with a QQQ.


In another embodiment, set forth herein is a kit comprising a glycopeptide standard, a buffer, and one or more glycopeptides consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In another embodiment, set forth herein is a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.





BRIEF DESCRIPTIONS OF THE DRAWINGS


FIGS. 1 through 14 illustrate glycan chemical structures, using the Symbol Nomenclature for Glycans (SNFG) system. Each glycan structure is associated with a glycan reference code number.



FIGS. 15 and 16 show work flows for detecting transitions 1-150 by mass spectroscopy.



FIGS. 17 through 19 show machine learning peak quantification analysis of mass spectroscopy data obtained by detecting transitions 1-150 by mass spectroscopy.



FIG. 20 is plot of ELISA results for measuring CA 125 protein in benign and malignant ovarian cancer samples, as set forth in Example 3.



FIG. 21 is a plot of probability of having cancer in benign and malignant ovarian cancer samples, as set forth in Example 4.





The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.


DETAILED DESCRIPTION

The following description is presented to enable one of ordinary skill in the art to make and use the invention and to incorporate it in the context of particular applications. Various modifications, as well as a variety of uses in different applications will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to a wide range of embodiments. Thus, the inventions herein are not intended to be limited to the embodiments presented, but are to be accorded their widest scope consistent with the principles and novel features disclosed herein.


All the features disclosed in this specification, (including any accompanying claims, abstract, and drawings) may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.


Please note, if used, the labels left, right, front, back, top, bottom, forward, reverse, clockwise and counter clockwise have been used for convenience purposes only and are not intended to imply any particular fixed direction. Instead, they are used to reflect relative locations and/or directions between various portions of an object.


I. GENERAL

The instant disclosure provides methods and compositions for the profiling, detecting, and/or quantifying of glycans in a biological sample. In some examples, glycan and glycopeptide panels are described for diagnosing and screening patients having ovarian cancer. In some examples, glycan and glycopeptide panels are described for diagnosing and screening patients having cancer, an autoimmune disease, or fibrosis.


Certain techniques for analyzing biological samples using mass spectroscopy are known. See, for example, International PCT Patent Application Publication No. WO2019079639A1, filed Oct. 18, 2018 as International Patent Application No. PCT/US2018/56574, and titled IDENTIFICATION AND USE OF BIOLOGICAL PARAMETERS FOR DIAGNOSIS AND TREATMENT MONITORING, the entire contents of which are herein incorporated by reference in its entirety for all purposes. See, also, US Patent Application Publication No. US20190101544A1, filed Aug. 31, 2018 as U.S. patent application Ser. No. 16/120,016, and titled IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND TREATMENT MONITORING, the entire contents of which are herein incorporated by reference in its entirety for all purposes.


II. DEFINITIONS

As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.


As used herein, the phrase “biological sample,” refers to a sample derived from, obtained by, generated from, provided from, take from, or removed from an organism; or from fluid or tissue from the organism. Biological samples include, but are not limited to synovial fluid, whole blood, blood serum, blood plasma, urine, sputum, tissue, saliva, tears, spinal fluid, tissue section(s) obtained by biopsy; cell(s) that are placed in or adapted to tissue culture; sweat, mucous, fecal material, gastric fluid, abdominal fluid, amniotic fluid, cyst fluid, peritoneal fluid, pancreatic juice, breast milk, lung lavage, marrow, gastric acid, bile, semen, pus, aqueous humor, transudate, and the like including derivatives, portions and combinations of the foregoing. In some examples, biological samples include, but are not limited, to blood and/or plasma. In some examples, biological samples include, but are not limited, to urine or stool. Biological samples include, but are not limited, to saliva. Biological samples include, but are not limited, to tissue dissections and tissue biopsies. Biological samples include, but are not limited, any derivative or fraction of the aforementioned biological samples.


As used herein, the term “glycan” refers to the carbohydrate residue of a glycoconjugate, such as the carbohydrate portion of a glycopeptide, glycoprotein, glycolipid or proteoglycan.


As used herein, the term “glycoform” refers to a unique primary, secondary, tertiary and quatemary structure of a protein with an attached glycan of a specific structure.


As used herein, the term “glycopeptide,” refers to a peptide having at least one glycan residue bonded thereto.


As used herein, the phrase “glycosylated peptides,” refers to a peptide bonded to a glycan residue.


As used herein, the phrase “glycopeptide fragment” or “glycosylated peptide fragment” refers to a glycosylated peptide (or glycopeptide) having an amino acid sequence that is the same as part (but not all) of the amino acid sequence of the glycosylated protein from which the glycosylated peptide is obtained by digestion, e.g., with one or more protease(s) or by fragmentation, e.g., ion fragmentation within a MRM-MS instrument. MRM refers to multiple-reaction-monitoring.


As used herein, the phrase “multiple reaction monitoring mass spectrometry (MRM-MS),” refers to a highly sensitive and selective method for the targeted quantification of glycans and peptides in biological samples. Unlike traditional mass spectrometry, MRM-MS is highly selective (targeted), allowing researchers to fine tune an instrument to specifically look for certain peptides fragments of interest. MRM allows for greater sensitivity, specificity, speed and quantitation of peptides fragments of interest, such as a potential biomarker. MRM-MS involves using one or more of a triple quadrupole (QQQ) mass spectrometer and a quadrupole time-of-flight (qTOF) mass spectrometer.


As used herein, the phrase “digesting a glycopeptide,” refers to a biological process that employs enzymes to break specific amino acid peptide bonds. For example, digesting a glycopeptide includes contacting a glycopeptide with an digesting enzyme, e.g., trypsin to produce fragments of the glycopeptide. In some examples, a protease enzyme is used to digest a glycopeptide. The term “protease” refers to an enzyme that performs proteolysis or breakdown of large peptides into smaller polypeptides or individual amino acids. Examples of a protease include, but are not limited to, one or more of a serine protease, threonine protease, cysteine protease, aspartate protease, glutamic acid protease, metalloprotease, asparagine peptide lyase, and any combinations of the foregoing.


As used herein, the phrase “fragmenting a glycopeptide,” refers to the ion fragmentation process which occurs in a MRM-MS instrument. Fragmenting may produce various fragments having the same mass but varying with respect to their charge.


As used herein, the term “subject,” refers to a mammal. The non-liming examples of a mammal include a human, non-human primate, mouse, rat, dog, cat, horse, or cow, and the like. Mammals other than humans can be advantageously used as subjects that represent animal models of disease, pre-disease, or a pre-disease condition. A subject can be male or female. However, in the context of diagnosing ovarian cancer, the subject is female unless explicitly specified otherwise. A subject can be one who has been previously identified as having a disease or a condition, and optionally has already undergone, or is undergoing, a therapeutic intervention for the disease or condition. Alternatively, a subject can also be one who has not been previously diagnosed as having a disease or a condition. For example, a subject can be one who exhibits one or more risk factors for a disease or a condition, or a subject who does not exhibit disease risk factors, or a subject who is asymptomatic for a disease or a condition. A subject can also be one who is suffering from or at risk of developing a disease or a condition.


As used herein, the term “patient” refers to a mammalian subject. The mammal can be a human, or an animal including, but not limited to an equine, porcine, canine, feline, ungulate, and primate animal. In one embodiment, the individual is a human. The methods and uses described herein are useful for both medical and veterinary uses. A “patient” is a human subject unless specified to the contrary.


As used herein, “peptide,” is meant to include glycopeptides unless stated otherwise.


As used herein, the phrase “multiple-reaction-monitoring (MRM) transition,” refers to the mass to charge (m/z) peaks or signals observed when a glycopeptide, or a fragment thereof, is detected by MRM-MS. The MRM transition is detected as the transition of the precursor and product ion.


As used herein, the phrase “detecting a multiple-reaction-monitoring (MRM) transition,” refers to the process in which a mass spectrometer analyzes a sample using tandem mass spectrometer ion fragmentation methods and identifies the mass to charge ratio for ion fragments in a sample. The absolute value of these identified mass to charge ratios are referred to as transitions. In the context of the methods set forth herein, the mass to charge ratio transitions are the values indicative of glycan, peptide or glycopeptide ion fragments. For some glycopeptides set forth herein, there is a single transition peak or signal. For some other glycopeptides set forth herein, there is more than one transition peak or signal. Background information on MRM mass spectrometry can be found in Introduction to Mass Spectrometry: Instrumentation, Applications, and Strategies for Data Interpretation, 4th Edition, J. Throck Watson, O. David Sparkman, ISBN: 978-0-470-51634-8, November 2007, the entire contents of which are here incorporated by reference in its entirety for all purposes.


As used herein, the phrase “detecting a multiple-reaction-monitoring (MRM) transition indicative of a glycopeptide,” refers to a MS process in which a MRM-MS transition is detected and then compare to a calculated mass to charge ratio (m/z) of a glycopeptide, or fragment thereof, in order to identify the glycopeptide. In some examples, herein, a single transition may be indicative of two more glycopeptides, if those glycopeptides have identical MRM-MS fragmentation patterns. A transition peak or signal includes, but is not limited to, those transitions set forth herein were are associated with a glycopeptide consisting essentially of an amino acid sequence selected from SEQ ID NOs:1-262, and combinations thereof, according to Tables 1-5, e.g., Table 1, Table 2, Table 3, Table 4, Table 5, or a combination thereof. A transition peak or signal includes, but is not limited to, those transitions set forth herein were are associated with a glycopeptide consisting of an amino acid sequence selected from SEQ ID NOs:1-262, and combinations thereof, according to Tables 1-5, e.g., Table 1, Table 2, Table 3, Table 4, Table 5, or a combination thereof.


As used herein, the term “reference value” refers to a value obtained from a population of individual(s) whose disease state is known. The reference value may be in n-dimensional feature space and may be defined by a maximum-margin hyperplane. A reference value can be determined for any particular population, subpopulation, or group of individuals according to standard methods well known to those of skill in the art.


As used herein, the term “population of individuals” means one or more individuals. In one embodiment, the population of individuals consists of one individual. In one embodiment, the population of individuals comprises multiple individuals. As used herein, the term “multiple” means at least 2 (such as at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30) individuals. In one embodiment, the population of individuals comprises at least 10 individuals.


As used herein, the term “treatment” or “treating” means any treatment of a disease or condition in a subject, such as a mammal, including: 1) preventing or protecting against the disease or condition, that is, causing the clinical symptoms not to develop; 2) inhibiting the disease or condition, that is, arresting or suppressing the development of clinical symptoms; and/or 3) relieving the disease or condition that is, causing the regression of clinical symptoms. Treating may include administering therapeutic agents to a subject in need thereof.


Herein, glycans are illustrated in FIGS. 1-15 using the Symbol Nomenclature for Glycans (SNFG) for illustrating glycans. An explanation of this illustration system is available on the internet at www.ncbi.nlm.nih.gov/glycans/snfg.html, the entire contents of which are herein incorporated by reference in its entirety for all purposes. Symbol Nomenclature for Graphical Representation of Glycans as published in Glycobiology 25: 1323-1324, 2015, which is available on the internet at doi.org/10.1093/glycob/cwv091. Additional information showing illustrations of the SNFG system are. Within this system, the term, Hex_i: is interpreted as follows: i indicates the number of green circles (mannose) and the number of yellow circles (galactose). The term, HexNAC_j, uses j to indicate the number of blue squares (GlcNAC's). The term Fuc_d, uses d to indicate the number of red triangles (fucose). The term Neu5AC_l, uses l to indicate the number of purple diamonds (sialic acid). The glycan reference codes used herein combine these i, j, d, and l terms to make a composite 4-5 number glycan reference code, e.g., 5300 or 5320. As an example, glycans 3200 and 3210 in FIG. 1 both include 3 green circles (mannose), 2 blue squares (GlcNAC's), and no purple diamonds (sialic acid) but differ in that glycan 3210 also includes 1 red triangle (fucose).


III. BIOMARKERS

Set forth herein are biomarkers. These biomarkers are useful for a variety of applications, including, but not limited to, diagnosing diseases and conditions. For example, certain biomarkers set forth herein, or combinations thereof, are useful for diagnosing ovarian cancer. In some other examples, certain biomarkers set forth herein, or combinations thereof, are useful for diagnosing and screening patients having cancer, an autoimmune disease, or fibrosis. In some examples, the biomarkers set forth herein, or combinations thereof, are useful for classifying a patient so that the patient receives the appropriate medical treatment. In some other examples, the biomarkers set forth herein, or combinations thereof, are useful for treating or ameliorating a disease or condition in patient by, for example, identifying a therapeutic agent with which to treat a patient. In some other examples, the biomarkers set forth herein, or combinations thereof, are useful for determining a prognosis of treatment for a patient or a likelihood of success or survivability for a treatment regimen.


In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of an amino acid sequence selected from SEQ ID NOs:1-262 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting essentially of an amino acid sequence selected from SEQ ID NOs:1-262 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs:1-262 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs:1-262 in the sample. In some examples, as described below, the presence, absolute amount, and/or relative amount of a glycopeptide is determined by analyzing the MS results. In some examples, the MS results are analyzed using machine learning.


In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting essentially of an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 in the sample. In some examples, as described below, the presence, absolute amount, and/or relative amount of a glycopeptide is determined by analyzing the MS results. In some examples, the MS results are analyzed using machine learning.


In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting essentially of an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194 in the sample. In some examples, as described below, the presence, absolute amount, and/or relative amount of a glycopeptide is determined by analyzing the MS results. In some examples, the MS results are analyzed using machine learning.


In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting essentially of an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196 in the sample. In some examples, a sample from a patient is analyzed by MS and the results are used to determine the presence, absolute amount, and/or relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196 in the sample. In some examples, as described below, the presence, absolute amount, and/or relative amount of a glycopeptide is determined by analyzing the MS results. In some examples, the MS results are analyzed using machine learning.


Set forth herein are biomarkers selected from glycans, peptides, glycopeptides, fragments thereof, and combinations thereof. In some examples, the glycopeptide consists of an amino acid sequence selected from SEQ ID NOs:1-262. In some examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NOs:1-262.


Set forth herein are biomarkers selected from glycans, peptides, glycopeptides, fragments thereof, and combinations thereof. In some examples, the glycopeptide consists of an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194. In some examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


Set forth herein are biomarkers selected from glycans, peptides, glycopeptides, fragments thereof, and combinations thereof. In some examples, the glycopeptide consists of an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194. In some examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194.


Set forth herein are biomarkers selected from glycans, peptides, glycopeptides, fragments thereof, and combinations thereof. In some examples, the glycopeptide consists of an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196. In some examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196.


a. O-Glycosylation

In some examples, the glycopeptides set forth herein include 0-glycosylated peptides. These peptides include glycopeptides in which a glycan is bonded to the peptide through an oxygen atom of an amino acid. Typically, the amino acid to which the glycan is bonded is threonine (T) or serine (S). In some examples, the amino acid to which the glycan is bonded is threonine (T). In some examples, the amino acid to which the glycan is bonded is serine (S).


In certain examples, the O-glycosylated peptides include those peptides from the group selected from Apolipoprotein C-III (APOC3), Alpha-2-HS-glycoprotein (FETUA), and combinations thereof. In certain examples, the O-glycosylated peptide, set forth herein, is an Apolipoprotein C-III (APOC3) peptide. In certain examples, the O-glycosylated peptide, set forth herein, is an Alpha-2-HS-glycoprotein (FETUA).


b. N-Glycosylation

In some examples, the glycopeptides set forth herein include N-glycosylated peptides. These peptides include glycopeptides in which a glycan is bonded to the peptide through a nitrogen atom of an amino acid. Typically, the amino acid to which the glycan is bonded is asparagine (N) or arginine (R). In some examples, the amino acid to which the glycan is bonded is asparagine (N). In some examples, the amino acid to which the glycan is bonded is arginine (R).


In certain examples, the N-glycosylated peptides include members selected from the group consisting of Alpha-1-antitrypsin (AIAT), Alpha-1B-glycoprotein (A1BG), Leucine-richAlpha-2-glycoprotein (A2GL), Alpha-2-macroglobulin (A2MG), Alpha-1-antichymotrypsin (AACT), Afamin (AFAM), Alpha-1-acid glycoprotein 1 & 2 (AGP12), Alpha-1-acid glycoprotein 1 (AGP1). Alpha-1-acid glycoprotein 2 (AGP2), Apolipoprotein A-I (APOA1), Apolipoprotein B-100 (APOB), Apolipoprotein D (APOD), Beta-2-glycoprotein-1 (APOH), Apolipoprotein M (APOM), Attractin (ATRN), Calpain-3 (CAN3), Ceruloplasmin (CERU), ComplementFactorH (CFAH), ComplementFactorI (CFAI), Clusterin (CLUS), ComplementC3 (CO3), ComplementC4-A&B (CO4A&CO4B), ComplementcomponentC6 (CO6), ComplementComponentC8AChain (CO8A), Coagulation factor XII (FA12), Haptoglobin (HPT), Histidine-rich Glycoprotein (HRG), Immunoglobulin heavy constant alpha 1&2 (IgA12), Immunoglobulin heavy constant alpha 2 (IgA2), Immunoglobulin heavy constant gamma 2 (IgG2), Immunoglobulin heavy constant mu (IgM), Inter-alpha-trypsin inhibitor heavy chain Hi (ITIH1), Plasma Kallikrein (KLKB1), Kininogen-1 (KNG1), Serum paraoxonase/arylesterase 1 (PON1), Selenoprotein P (SEPP1), Prothrombin (THRB), Serotransferrin (TRFE), Transthyretin (TTR), Protein unc-13HomologA (UN13A), Vitronectin (VTNC), Zinc-alpha-2-glycoprotein (ZA2G), Insulin-like growth factor-II (IGF2), Apolipoprotein C-I (APOC1), and combinations thereof.


c. Peptides and Glycopeptides

In some examples, set forth herein is a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof.


In some examples, set forth herein is a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:1. In some examples, the glycopeptide comprises either glycans 6501 or 6520, or both, wherein the glycan(s) are bonded to residue 107. In some examples, the glycopeptide is A1AT-GP001_107_6501/6520. Herein AlAT refers to Alpha-1-antitrypsin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:2. In some examples, the glycopeptide comprises glycan 6513 at residue 107. In some examples, the glycopeptide is A1AT-GP001_107_6513.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:3. In some examples, the glycopeptide comprises glycan 5401 at residue 271. In some examples, the glycopeptide is A1AT-GP001_271_5401.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:4. In some examples, the glycopeptide comprises glycan 5402 at residue 271. In some examples, the glycopeptide is A1AT-GP001_271_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:5. In some examples, the glycopeptide comprises glycan 5402 at residue 271. In some examples, the glycopeptide is A1AT-GP001_271MC_5402. Herein, “MC” refers to a missed cleavage of a trypsin digestion. A missed cleavage peptide includes the amino acid sequence selected from SEQ ID NO:5 but also includes additional residues which were not cleaved by way of trypsin digestion.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:6. In some examples, the glycopeptide comprises glycan 5402 at residue 70. In some examples, the glycopeptide is ATAT-GP001_70_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:7. In some examples, the glycopeptide comprises glycan 5412 at residue 70. In some examples, the glycopeptide is A1AT-GP001_70_5412.


In certain examples, the peptide comprises an amino acid sequence selected from SEQ ID NO:8. In some examples, the glycopeptide is QuantPep-A1AT-GP001.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:9. In some examples, the glycopeptide comprises glycans 5401 or 5402, or both, at residue 179. In some examples, the glycopeptide is A1BG-GP002_179_5421/5402. Herein, when two glycans are recited with a forward slash (/) between them, this means, unless specified otherwise explicitly, that the mass spectrometry method is unable to distinguish between these two glycans, e.g., because they share a common mass to charge ratio. Unless specified to the contrary, 5421/5402 means that either glycan 5421 or 5402 is present. The quantification of the amount of glycans 5421/5402 includes a summation of the detected amount of glycan 5421 as well as the detected amount of glycan 5402. Herein A1BG refers to Alpha-1B-glycoprotein.


In certain examples, the peptide comprises an amino acid sequence selected from SEQ ID NO:10. In some examples, the peptide is pep-A2GL-GP003. Herein A2GL refers to Leucine-richAlpha-2-glycoprotein.


In certain examples, the peptide comprises an amino acid sequence selected from SEQ ID NO:11. In some examples, the glycopeptide is QuantPep-A2GL-GP003.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:12. In some examples, the glycopeptide comprises glycan 5402 at residue 1424. In some examples, the glycopeptide is A2MG-GP004_1424_5402. Herein A2MG refers to Alpha-2-macroglobulin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:13, In some examples, the glycopeptide comprises glycan 5402 at residue 1424. In some examples, the glycopeptide is A2MG-GP004_1424_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:14. In some examples, the glycopeptide comprises glycan 5402 at residue 1424. In some examples, the glycopeptide is A2MG-GP004_1424_5402_z3. Herein, z3 refers to the charge state (i.e., +3) for the detected glycopeptide fragment.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:15. In some examples, the glycopeptide comprises glycan 5401 at residue 1424. In some examples, the glycopeptide is A2MG-GP004_1424_5402_z3.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:16. In some examples, the glycopeptide comprises glycan 5402 at residue 1424. In some examples, the glycopeptide is A2MG-GP004_1424_5402_z5.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:17. In some examples, the glycopeptide comprises glycan 5402 at residue 1424. In some examples, the glycopeptide is A2MG-GP004_1424_5402_z5. Herein, z5 refers to the charge state (i.e., +5) for the detected glycopeptide fragment.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:18. In some examples, the glycopeptide comprises glycan 5200 at residue 247. In some examples, the glycopeptide is A2MG-GP004_247_5200.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:19. In some examples, the glycopeptide comprises glycan 5200 at residue 247. In some examples, the glycopeptide is A2MG-GP004_247_5200.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:20. In some examples, the glycopeptide comprises glycan 5402 at residue 247. In some examples, the glycopeptide is A2MG-GP004_247_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:21. In some examples, the glycopeptide comprises glycan 5402 at residue 247. In some examples, the glycopeptide is A2MG-GP004_247_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:22. In some examples, the glycopeptide comprises glycan 5402 at residue 55. In some examples, the glycopeptide is A2MG-GP004_55_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:23. In some examples, the glycopeptide comprises glycan 5402 at residue 55. In some examples, the glycopeptide is A2MG-GP004_55_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:24. In some examples, the glycopeptide comprises glycan 5401 at residue 869. In some examples, the glycopeptide is A2MG-GP004_869_5401.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:25. In some examples, the glycopeptide comprises glycan 5401 at residue 869. In some examples, the glycopeptide is A2MG-GP004_869_5401.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:26. In some examples, the glycopeptide comprises glycan 5402 at residue 869. In some examples, the glycopeptide is A2MG-GP004_869_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:27. In some examples, the glycopeptide comprises glycan 5402 at residue 869. In some examples, the glycopeptide is A2MG-GP004_869_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:28. In some examples, the glycopeptide comprises glycan 6301 at residue 869. In some examples, the glycopeptide is A2MG-GP004_869_6301.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:29. In some examples, the glycopeptide comprises glycan 6301 at residue 869. In some examples, the glycopeptide is A2MG-GP004_869_6301.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:30. In some examples, the glycopeptide comprises glycan 7602 at residue 271. In some examples, the glycopeptide is AACT-GP005_271_7602. Herein AACT refers to Alpha-1-antichymotrypsin.


In certain examples, the peptide comprises an amino acid sequence selected from SEQ ID NO:31. In some examples, the glycopeptide is QuantPep-AACT-GP005.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:32. In some examples, the glycopeptide comprises glycan 5402 at residue 33. In some examples, the glycopeptide is AFAM-GP006_33_5402. Herein, AFAM refers to Afamin.


In certain examples, the peptide comprises an amino acid sequence selected from SEQ ID NO:33. In some examples, the glycopeptide is QuantPep-AFAM-GP006.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:34. In some examples, the glycopeptide comprises glycan 6503 at residue 72MC. In some examples, the glycopeptide is AGP12-GP007&008_72MC_6503. Herein AGP12 refers to Alpha-1-acid glycoprotein 1&2.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:35. In some examples, the glycopeptide comprises glycan 7601 at residue 72MC. In some examples, the glycopeptide is AGP12-GP007&008_72MC_7601.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:36. In some examples, the glycopeptide comprises glycan 7602 at residue 72MC. In some examples, the glycopeptide is AGP12-GP007&008_72MC_7602.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:37. In some examples, the glycopeptide comprises glycan 7603 at residue 72MC. In some examples, the glycopeptide is AGP12-GP007&008_72MC_7603.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:38. In some examples, the glycopeptide comprises glycan 7613 at residue 72MC. In some examples, the glycopeptide is AGP12-GP007&008_72MC_7613.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:39. In some examples, the glycopeptide comprises glycan 7614 at residue 72MC. In some examples, the glycopeptide is AGP12-GP007&008_72MC_7614.


In certain examples, the peptide comprises an amino acid sequence selected from SEQ ID NO:40. In some examples, the glycopeptide is QuantPep-AGP12-GP007&008.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:41. In some examples, the glycopeptide comprises glycan 6513 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_6513. Herein AGP1 refers to Alpha-1-acid glycoprotein 1.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:42. In some examples, the glycopeptide comprises glycan 6513 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_6513.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:43. In some examples, the glycopeptide comprises glycan 7602 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_7602.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:44. In some examples, the glycopeptide comprises glycan 7602 at residue 103. In some examples, the glycopeptide is AGPT-GP007_103_7602.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:45. In some examples, the glycopeptide comprises glycan 7614 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_7614.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:46. In some examples, the glycopeptide comprises glycan 7614 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_7614.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:47. In some examples, the glycopeptide comprises glycan 7624 at residue 103. In some examples, the glycopeptide is AGPT-GP007_103_7624.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:48. In some examples, the glycopeptide comprises glycan 7624 at residue 103. In some examples, the glycopeptide is AGPT-GP007_103_7624.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:49. In some examples, the glycopeptide comprises glycan 8704 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_8704.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:50. In some examples, the glycopeptide comprises glycan 8704 at residue 103. In some examples, the glycopeptide is AGPT-GP007_103_8704.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:51. In some examples, the glycopeptide comprises glycan 9804 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_9804.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:52. In some examples, the glycopeptide comprises glycan 9804 at residue 103. In some examples, the glycopeptide is AGP1-GP007_103_9804.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:53. In some examples, the glycopeptide comprises glycan 5402 at residue 33. In some examples, the glycopeptide is AGPT-GP007_33_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:54. In some examples, the glycopeptide comprises glycan 5402 at residue 33. In some examples, the glycopeptide is AGPT-GP007_33_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:55. In some examples, the glycopeptide comprises glycan 6501 at residue 33. In some examples, the glycopeptide is AGP1-GP007_33_6501.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:56. In some examples, the glycopeptide comprises glycan 6501 at residue 33. In some examples, the glycopeptide is AGP1-GP007_33_6501.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:57. In some examples, the glycopeptide comprises glycan 6502 at residue 33. In some examples, the glycopeptide is AGP1-GP007_33_6502.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:58. In some examples, the glycopeptide comprises glycan 6502 at residue 33. In some examples, the glycopeptide is AGPT-GP007_33_6502.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:59. In some examples, the glycopeptide comprises glycan 6500 at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_6500.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:60. In some examples, the glycopeptide comprises glycan 6500 at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_6500.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:61. In some examples, the glycopeptide comprises glycan 6513 at residue 93. In some examples, the glycopeptide is AGPT-GP007_93_6513.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:62. In some examples, the glycopeptide comprises glycan 6513 at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_6513.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:63. In some examples, the glycopeptide comprises glycans 7602 or 7621, or both, at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_7602/7621.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:64. In some examples, the glycopeptide comprises glycans 7602 or 7621, or both, at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_7602/7621.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:65. In some examples, the glycopeptide comprises glycans 7603 or 7622, or both, at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_7603/7622.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:66. In some examples, the glycopeptide comprises glycans 7603 or 7622, or both, at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_7603/7622.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:67. In some examples, the glycopeptide comprises glycan 7611 at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_7611.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:68. In some examples, the glycopeptide comprises glycan 7611 at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_7611.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:69. In some examples, the glycopeptide comprises glycan 7613 at residue 93. In some examples, the glycopeptide is AGPT-GP007_93_7613.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:70. In some examples, the glycopeptide comprises glycan 7613 at residue 93. In some examples, the glycopeptide is AGP1-GP007_93_7613.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:71. In some examples, the glycopeptide is pep-AGP1-GP007.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:72. In some examples, the glycopeptide is pep-AGP1-GP007.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:73. In some examples, the glycopeptide is QuantPep-AGP1-GP007.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:74. In some examples, the glycopeptide comprises glycan 6503 at residue 103. In some examples, the glycopeptide is AGP2-GP008_103_6503. Herein AGP2 refers to Alpha-1-acid glycoprotein 2.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:75. In some examples, the glycopeptide comprises glycan 6503 at residue 103. In some examples, the glycopeptide is AGP2-GP008_103_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:76. In some examples, the glycopeptide is pep-APOA1-GP011. Herein APOA1 refers to Apolipoprotein A-I.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:77. In some examples, the glycopeptide is pep-APOA1-GP011.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:78. In some examples, the glycopeptide is QuantPep-APOA1-GP011.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:79. In some examples, the glycopeptide is QuantPep-APOA1-GP011.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:80. In some examples, the glycopeptide comprises glycan 0310 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_0310. Herein APOC3 refers to Apolipoprotein C-III.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:81. In some examples, the glycopeptide comprises glycan 0310 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_0310.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:82. In some examples, the glycopeptide comprises glycan 1102 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_1102.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:83. In some examples, the glycopeptide comprises glycan 1102 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_1102.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:84. In some examples, the glycopeptide comprises glycan 1111 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_1111.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:85. In some examples, the glycopeptide comprises glycan 1111 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_1111.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:86. In some examples, the glycopeptide comprises glycan 2110 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_2110.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:87. In some examples, the glycopeptide comprises glycan 2110 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74_2110.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:88. In some examples, the glycopeptide comprises glycan 1102 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74Aoff_1102. As used herein, “Aoff” refers to a peptide sequence that differs by the removal of one alanine residue as a result of digestion in serum.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:89. In some examples, the glycopeptide comprises glycan 110 2 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74Aoff_1102.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:90. In some examples, the glycopeptide comprises glycan 1101 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74MC_1101.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:91. In some examples, the glycopeptide comprises glycan 1101 at residue 74. In some examples, the glycopeptide is APOC3-GP012_74MC_1101.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:92. In some examples, the glycopeptide comprises glycan 5401 at residue 3411. In some examples, the glycopeptide is APOB-GP013_3411_5401. Herein APOB refers to Apolipoprotein B-100.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:93. In some examples, the glycopeptide comprises glycans 5402 or 5421, or both, at residue 98. In some examples, the glycopeptide is APOD-GP014_98_5402/5421. Herein APOD refers to Apolipoprotein D.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:94. In some examples, the glycopeptide comprises glycan 5410 at residue 98. In some examples, the glycopeptide is APOD-GP014_98_5410.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:95. In some examples, the glycopeptide comprises glycan 6510 at residue 98. In some examples, the glycopeptide is APOD-GP014_98_6510.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:96. In some examples, the glycopeptide comprises glycan 6530 at residue 98. In some examples, the glycopeptide is APOD-GP014_98_6530.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:97. In some examples, the glycopeptide comprises glycan 9800 at residue 98. In some examples, the glycopeptide is APOD-GP014_98_9800.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:98. In some examples, the glycopeptide is QuantPep-APOD-GP014.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:99. In some examples, the glycopeptide comprises glycan 5401 at residue 253. In some examples, the glycopeptide is APOH-GP015_253_5401. Herein APOH refers to Beta-2-glycoprotein1.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:100. In some examples, the glycopeptide is QuantPep-APOM-GP016. Herein APOM refers to Apolipoprotein M.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:101. In some examples, the glycopeptide is pep-APOM-GP016.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:102. In some examples, the glycopeptide is QuantPep-ATRN-GP018. Herein ATRN refers to Attractin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:103. In some examples, the glycopeptide comprises glycan 6513 at residue 366. In some examples, the glycopeptide is CAN3-GP022_366_6513. Herein CAN3 refers to Calpain-3.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:104. In some examples, the glycopeptide comprises glycan 6503 at residue 138. In some examples, the glycopeptide is CERU-GP023_138_6503, Herein CERU refers to Ceruloplasmin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:105. In some examples, the glycopeptide comprises glycan 5431 at residue 1029. In some examples, the glycopeptide is CFAH-GP024_1029_5431. Herein CFAH refers to ComplementFactorH.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:106. In some examples, the glycopeptide comprises glycan 7500 at residue 1029. In some examples, the glycopeptide is CFAH-GP024_1029_7500.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:107. In some examples, the glycopeptide comprises glycans 5420 or 5401, or both, at residue 882. In some examples, the glycopeptide is CFAH-GP024_882_5420/5401.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:108. In some examples, the glycopeptide comprises glycans 5402 or 5421, or both, at residue 911. In some examples, the glycopeptide is CFAH-GP024_911_5402/5421.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:109. In some examples, the glycopeptide comprises glycan 5401 at residue 70. In some examples, the glycopeptide is CFAI-GP025_70_5401. Herein CFAI refers to ComplementFactorI.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:110. In some examples, the glycopeptide comprises glycan 5402 at residue 70. In some examples, the glycopeptide is CFAI-GP025_70_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:111. In some examples, the glycopeptide comprises glycan 6503 at residue 291. In some examples, the glycopeptide is CLUS-GP026_291_6503. Herein CLUS refers to Clusterin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:112. In some examples, the glycopeptide comprises glycan 6503 at residue 86. In some examples, the glycopeptide is CLUS-GP026_86_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:113. In some examples, the glycopeptide is QuantPep-CLUS-GP026.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:114. In some examples, the glycopeptide comprises glycan 5200 at residue 85. In some examples, the glycopeptide is CO3-GP028_85_5200. Herein CO3 refers to ComplementC3.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:115. In some examples, the glycopeptide comprises glycan 5402 at residue 1328. In some examples, the glycopeptide is CO4A&CO4B-GP029&030_1328_5402. Herein CO4A&CO4B refers to ComplementC4-A&B.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:116. In some examples, the glycopeptide comprises glycan 5402 at residue 1328. In some examples, the glycopeptide is CO4A&CO4B-GP029&030_1328_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:117. In some examples, the glycopeptide is pep-CO6-GP032. Herein CO6 refers to ComplementcomponentC6.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:118. In some examples, the glycopeptide comprises glycan 5200 at residue 437. In some examples, the glycopeptide is CO8A-GP033_437_5200. Herein, CO8a refers to ComplementComponentC8AChain.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:119. In some examples, the glycopeptide is QuantPep-CO8A-GP033.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:120. In some examples, the glycopeptide comprises glycan 5410 at residue 553. In some examples, the glycopeptide is CO8B-GP034_553_5410. Herein CO8B refers to ComplementComponentC8AChain.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:121. In some examples, the glycopeptide is QuantPep-FA12-GP035. Herein FA12 refers to Coagulation factor XII.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:122. In some examples, the glycopeptide comprises glycan 5401 at residue 156. In some examples, the glycopeptide is FETUA-GP036_156_5400. Herein FETUA refers to Alpha-2-HS-glycoprotein.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:123. In some examples, the glycopeptide comprises glycan 5401 at residue 176. In some examples, the glycopeptide is FETUA-GP036_176_5401.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:124. In some examples, the glycopeptide comprises glycan 2200 at residue 346. In some examples, the glycopeptide is FETUA-GP036_346_2200.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:125. In some examples, the glycopeptide is QuantPep-FETUA-GP036.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:126. In some examples, the glycopeptide comprises glycan 11904 at residue 207. In some examples, the glycopeptide is HPT-GP044_207_11904. Herein HPT refers to Haptoglobin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:127. In some examples, the glycopeptide comprises glycan 11904 at residue 207. In some examples, the glycopeptide is HPT-GP044_207_11904.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:128. In some examples, the glycopeptide comprises glycan 11915 at residue 207. In some examples, the glycopeptide is HPT-GP044_207_11915.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:129. In some examples, the glycopeptide comprises glycan 11915 at residue 207. In some examples, the glycopeptide is HPT-GP044_207_11915.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:130. In some examples, the glycopeptide comprises glycan 121005 at residue 207. In some examples, the glycopeptide is HPT-GP044_207_121005.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:131. In some examples, the glycopeptide comprises glycan 121005 at residue 207. In some examples, the glycopeptide is HPT-GP044_207_121005.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:132. In some examples, the glycopeptide comprises glycan 6503 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:133. In some examples, the glycopeptide comprises glycan 6503 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:134. In some examples, the glycopeptide comprises glycan 6512 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_6512.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:135. In some examples, the glycopeptide comprises glycan 6512 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_6512.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:136. In some examples, the glycopeptide comprises glycan 6513 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_6513.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:137. In some examples, the glycopeptide comprises glycan 6513 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_6513.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:138. In some examples, the glycopeptide comprises glycan 7613 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_7613.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:139. In some examples, the glycopeptide comprises glycan 7613 at residue 241. In some examples, the glycopeptide is HPT-GP044_241_7613.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:140. In some examples, the glycopeptide is pep-HPT-GP044.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:141. In some examples, the glycopeptide is QuantPep-HPT-GP044.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:142. In some examples, the glycopeptide comprises glycans 5421 or 5402, or both, at residue 271. In some examples, the glycopeptide is HRG-GP045_125_5421/5402. Herein HRG refers to Histidine-rich Glycoprotein.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:143. In some examples, the glycopeptide comprises glycan 5412 at residue 345. In some examples, the glycopeptide is HRG-GP045_345_5412.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:144. In some examples, the glycopeptide comprises glycan 5502 at residue 144. In some examples, the glycopeptide is IgA12-GP046&047_144_5502. Herein IgA12 refers to Immunoglobulin heavy constant alpha 1&2.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:145. In some examples, the glycopeptide comprises glycan 5411 at residue 205. In some examples, the glycopeptide is IgA2-GP047_205_5411. Herein IgA2 refers to Immunoglobulin heavy constant alpha 2.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:146. In some examples, the glycopeptide comprises glycan 5412 at residue 205. In some examples, the glycopeptide is IgA2-GP047_205_5412.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:147. In some examples, the glycopeptide comprises glycan 5510 at residue 205. In some examples, the glycopeptide is IgA2-GP047_205_5510.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:148. In some examples, the glycopeptide comprises glycan 3410 at residue 297. In some examples, the glycopeptide is IgG2-GP049_297_3410. Herein IgG2 refers to Immunoglobulin heavy constant gamma 2.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:149. In some examples, the glycopeptide comprises glycan 3410 at residue 297. In some examples, the glycopeptide is IgG2-GP049_297_3410.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:150. In some examples, the glycopeptide comprises glycan 4411 at residue 297. In some examples, the glycopeptide is IgG2-GP049_297_4411.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:151. In some examples, the glycopeptide comprises glycan 4411 at residue 297. In some examples, the glycopeptide is IgG2-GP049_297_4411.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:152. In some examples, the glycopeptide is QuantPep-IgG2-GP049.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:153. In some examples, the glycopeptide is QuantPep-IgG2-GP049.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:154. In some examples, the glycopeptide comprises glycan 6200 at residue 439. In some examples, the glycopeptide is IgM-GP053_439_6200. Herein IgM refers to Immunoglobulin heavy constant mu.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:155. In some examples, the glycopeptide comprises glycan 6200 at residue 439. In some examples, the glycopeptide is IgM-GP053_439_6200.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:156. In some examples, the glycopeptide comprises glycan 5601 at residue 46. In some examples, the glycopeptide is IgM-GP053_46_5601.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:157. In some examples, the glycopeptide comprises glycan 5601 at residue 46. In some examples, the glycopeptide is IgM-GP053_46_5601.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:158. In some examples, the glycopeptide comprises glycan 5511 at residue 285. In some examples, the glycopeptide is ITIH1-GP054_285_5511. Herein ITIH1 refers to Inter-alpha-trypsin inhibitor heavy chain H1.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:159. In some examples, the glycopeptide is QuantPep-ITIH1-GP054.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:160. In some examples, the glycopeptide comprises glycans 5420 or 5401, or both, at residue 271. In some examples, the glycopeptide is ITIH4-GP055_517_5420/5401. Herein ITIH4 refers to Inter-alpha-trypsin inhibitor heavy chain H4.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:161. In some examples, the glycopeptide comprises glycan 5400 at residue 494. In some examples, the glycopeptide is KLKB1-GP056_494_5400. Herein KLKB1 refers to Plasma Kallikrein.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:162. In some examples, the glycopeptide comprises glycan 5402 at residue 494. In some examples, the glycopeptide is KLKB1-GP056_494_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:163. In some examples, the glycopeptide comprises glycan 6503 at residue 494. In some examples, the glycopeptide is KLKBT-GP056_494_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:164. In some examples, the glycopeptide is QuantPep-KLKB1-GP056.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:165. In some examples, the glycopeptide is QuantPep-KNG1-GP057. Herein KNG1 refers to Kininogen-1.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:166. In some examples, the glycopeptide comprises glycan 4301 at residue 271. In some examples, the glycopeptide is PON1-GP060_253_4301. Herein PON1 refers to Serum paraoxonase/arylesterase 1.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:167. In some examples, the glycopeptide comprises glycan 5420 at residue 324. In some examples, the glycopeptide is PON1-GP060_324_5420.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:168. In some examples, the glycopeptide comprises glycan 6501 at residue 324. In some examples, the glycopeptide is PON1-GP060_324_6501.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:169. In some examples, the glycopeptide comprises glycan 6502 at residue 324. In some examples, the glycopeptide is PON1-GP060_324_6502.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:170. In some examples, the glycopeptide is QuantPep-PON1-GP060.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:171. In some examples, the glycopeptide is QuantPep-SEPP1-GP061. Herein SEPP1 refers to Selenoprotein P.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:172. In some examples, the glycopeptide comprises glycans 5420 or 5401, or both, at residue 121. In some examples, the glycopeptide is THRB-GP063_121_5420/5401. Herein THRM refers to Prothrombin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:173. In some examples, the glycopeptide comprises glycans 5420 or 5401, or both, at residue 121. In some examples, the glycopeptide is THRB-GP063_121_5421/5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:174. In some examples, the glycopeptide is pep-TRFE-GP064. Herein TRFE refers to Serotransferrin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:175. In some examples, the glycopeptide is QuantPep-TRFE-GP064.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:176. In some examples, the glycopeptide comprises glycan 5401 at residue 432. In some examples, the glycopeptide is TRFE-GP064_432_5401.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:177. In some examples, the glycopeptide comprises glycan 5402 at residue 432. In some examples, the glycopeptide is TRFE-GP064_432_5402.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:178. In some examples, the glycopeptide comprises glycan 5412 at residue 432. In some examples, the glycopeptide is TRFE-GP064_432_5412.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:179. In some examples, the glycopeptide comprises glycan 5400 at residue 630. In some examples, the glycopeptide is TRFE-GP064_630_5400.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:180. In some examples, the glycopeptide comprises glycan 6410 at residue 630. In some examples, the glycopeptide is TRFE-GP064_630_6410.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:181. In some examples, the glycopeptide comprises glycan 6411 at residue 630. In some examples, the glycopeptide is TRFE-GP064_630_6411.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:182. In some examples, the glycopeptide comprises glycan 6502 at residue 630. In some examples, the glycopeptide is TRFE-GP064_630_6502.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:183. In some examples, the glycopeptide comprises glycan 6503 at residue 630. In some examples, the glycopeptide is TRFE-GP064_630_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:184. In some examples, the glycopeptide comprises glycan 6513 at residue 630. In some examples, the glycopeptide is TRFE-GP064_630_6513.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:185. In some examples, the glycopeptide is QuantPep-TTR-GP065. Herein TTR refers to Transthyretin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:186. In some examples, the glycopeptide is QuantPep-UN13A-GP066. Herein UN13A refers to Protein unc-13HomologA.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:187. In some examples, the glycopeptide comprises glycan 3420 at residue 1005. In some examples, the glycopeptide is UN13A-GP066_1005_3420.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:188. In some examples, the glycopeptide comprises glycan 5431 at residue 1005. In some examples, the glycopeptide is UN13A-GP066_1005_5431.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:189. In some examples, the glycopeptide comprises glycan 7420 at residue 1005. In some examples, the glycopeptide is UN13A-GP066_1005_7420.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:190. In some examples, the glycopeptide comprises glycan 5401 at residue 169. In some examples, the glycopeptide is VTNC-GP067_169_5401. Herein VTNC refers to Vitronectin.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:191. In some examples, the glycopeptide comprises glycan 5401 at residue 169. In some examples, the glycopeptide is VTNC-GP067_169_5401.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:192. In some examples, the glycopeptide comprises glycan 6502 at residue 242. In some examples, the glycopeptide is VTNC-GP067_242_6502.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:193. In some examples, the glycopeptide comprises glycan 6502 at residue 242. In some examples, the glycopeptide is VTNC-GP067_242_6502.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:194. In some examples, the glycopeptide comprises glycan 6503 at residue 242. In some examples, the glycopeptide is VTNC-GP067_242_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:195. In some examples, the glycopeptide comprises glycan 6503 at residue 242. In some examples, the glycopeptide is VTNC-GP067_242_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:196. In some examples, the glycopeptide comprises glycan 6503 at residue 86. In some examples, the glycopeptide is VTNC-GP067_86_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:197. In some examples, the glycopeptide comprises glycan 6503 at residue 86. In some examples, the glycopeptide is VTNC-GP067_86_6503.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:198. In some examples, the glycopeptide comprises glycan 5412 at residue 112. In some examples, the glycopeptide is ZA2G-GP068_112_5412. Herein ZA2G refers to Zinc-alpha-2-glycoprotein.


In certain examples, the glycopeptide consists essentially of an amino acid sequence selected from SEQ ID NO:199. In some examples, the glycopeptide comprises glycan 5412 at residue 112. In some examples, the glycopeptide is ZA2G-GP068_112_5412.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:200. In some examples, the glycopeptide is pep-IGF2. Herein IGF2 refers to Insulin-like growth factor-II.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:201. In some examples, the glycopeptide is pep-APOC1. Herein APOC1 refers to Apolipoprotein C-1.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:202. In some examples, the glycopeptide is pep-RET4.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:203.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:204.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:205.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:206.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:207.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:208.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:209.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:210.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:211.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:212.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:213.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:214.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:215.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:216.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:217.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:218.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:219.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:220.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:221.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:222.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:223.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:224.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:225.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:226.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:227.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:228.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:229.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:230.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:231.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:232.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:233.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:234.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:235.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:236.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:237.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:238.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:239.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:240.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:241.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:242.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:243.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:244.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:245.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:246.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:247.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:248.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:249.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:250.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:251.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:252.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:253.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:254.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:255.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:256.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:257.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:258.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:259.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:260.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:261.


In certain examples, set forth herein is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NO:262.


In some examples, including any of the foregoing, the glycopeptide is a combination of amino acid sequences selected from SEQ ID NOs:1-262.


In some examples, including any of the foregoing, set forth herein is one or more peptides, in which each peptide, individually in each instance, is a peptide consisting of an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, set forth herein is one or more peptides, in which each peptide, individually in each instance, is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, set forth herein is one or more peptides, in which each peptide, individually in each instance, is a peptide consisting of an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194, and combinations thereof.


In some examples, including any of the foregoing, set forth herein is one or more peptides, in which each peptide, individually in each instance, is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, and 194, and combinations thereof.


In some examples, including any of the foregoing, set forth herein is one or more peptides, in which each peptide, individually in each instance, is a peptide consisting of an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196, and combinations thereof.


In some examples, including any of the foregoing, set forth herein is one or more peptides, in which each peptide, individually in each instance, is a peptide consisting essentially of an amino acid sequence selected from SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190 and 196, and combinations thereof.


IV. METHODS OF USING BIOMARKERS

A. Methods for Detecting Glycopeptides


In some embodiments, set forth herein is a method for detecting one or more a multiple-reaction-monitoring (MRM) transition, comprising: obtaining a biological sample from a patient, wherein the biological sample comprises one or more glycopeptides; digesting and/or fragmenting a glycopeptide in the sample; and detecting a multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150. These transitions may include, in various examples, any one or more of the transitions in Tables 1-5. These transitions may include, in various examples, any one or more of the transitions in Tables 1-3. These transitions may include, in various examples, any one or more of the transitions in Table 1. These transitions may include, in various examples, any one or more of the transitions in Table 2. These transitions may include, in various examples, any one or more of the transitions in Table 3. These transitions may include, in various examples, any one or more of the transitions in Table 4. These transitions may include, in various examples, any one or more of the transitions in Table 5. These transitions may be indicative of glycopeptides.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190, 196, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 7, 14, 15, 20, 24, 25, 27, 40, 52, 98, 99, 104, 116, 177, 190, 196, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, 194, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides, wherein each glycopeptide is individually in each instance selected from a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 12, 22, 28, 32, 35, 36, 38, 53, 65, 69, 99, 104, 115, 128, 146, 154, 177, 190, 194, and combinations thereof.


In some examples, set forth herein is a method of detecting one or more glycopeptides. In some examples, set forth herein is a method of detecting one or more glycopeptide fragments. In certain examples, the method includes detecting the glycopeptide group to which the glycopeptide, or fragment thereof, belongs. In some of these examples, the glycopeptide group is selected from Alpha-1-antitrypsin (AIAT), Alpha-1B-glycoprotein (AlBG), Leucine-richAlpha-2-glycoprotein (A2GL), Alpha-2-macroglobulin (A2MG), Alpha-1-antichymotrypsin (AACT), Afamin (AFAM), Alpha-1-acid glycoprotein 1 & 2 (AGP12), Alpha-1-acid glycoprotein 1 (AGP1), Alpha-1-acid glycoprotein 2 (AGP2), Apolipoprotein A-I (APOA1), Apolipoprotein C-III (APOC3), Apolipoprotein B-100 (APOB), Apolipoprotein D (APOD), Beta-2-glycoprotein-1 (APOH), Apolipoprotein M (APOM), Attractin (ATRN), Calpain-3 (CAN3), Ceruloplasmin (CERU), ComplementFactorH (CFAH), ComplementFactorI (CFAI), Clusterin (CLUS), ComplementC3 (CO3), ComplementC4-A&B (CO4A&CO4B), ComplementcomponentC6 (CO6), ComplementComponentC8AChain (CO8A), Coagulation factor XII (FA12), Alpha-2-HS-glycoprotein (FETUA), Haptoglobin (HPT), Histidine-rich Glycoprotein (HRG), Immunoglobulin heavy constant alpha 1&2 (IgA12), Immunoglobulin heavy constant alpha 2 (IgA2), Immunoglobulin heavy constant gamma 2 (IgG2), Immunoglobulin heavy constant mu (IgM), Inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1), Plasma Kallikrein (KLKB1), Kininogen-1 (KNG1), Serum paraoxonase/arylesterase 1 (PON1), Selenoprotein P (SEPP1), Prothrombin (THRB), Serotransferrin (TRFE), Transthyretin (TTR), Protein unc-13HomologA (UN13A), Vitronectin (VTNC), Zinc-alpha-2-glycoprotein (ZA2G), Insulin-like growth factor-II (IGF2), Apolipoprotein C-I (APOC1), and combinations thereof.


In some examples, including any of the foregoing, the method includes detecting a glycopeptide, a glycan on the glycopeptide and the glycosylation site residue where the glycan bonds to the glycopeptide. In certain examples, the method includes detecting a glycan residue. In some examples, the method includes detecting a glycosylation site on a glycopeptide. In some examples, this process is accomplished with mass spectroscopy used in tandem with liquid chromatography.


In some examples, including any of the foregoing, the method includes obtaining a biological sample from a patient. In some examples, the biological sample is synovial fluid, whole blood, blood serum, blood plasma, urine, sputum, tissue, saliva, tears, spinal fluid, tissue section(s) obtained by biopsy; cell(s) that are placed in or adapted to tissue culture; sweat, mucous, fecal material, gastric fluid, abdominal fluid, amniotic fluid, cyst fluid, peritoneal fluid, pancreatic juice, breast milk, lung lavage, marrow, gastric acid, bile, semen, pus, aqueous humour, transudate, or combinations of the foregoing. In certain examples, the biological sample is selected from the group consisting of blood, plasma, saliva, mucus, urine, stool, tissue, sweat, tears, hair, or a combination thereof. In some of these examples, the biological sample is a blood sample. In some of these examples, the biological sample is a plasma sample. In some of these examples, the biological sample is a saliva sample. In some of these examples, the biological sample is a mucus sample. In some of these examples, the biological sample is a urine sample. In some of these examples, the biological sample is a stool sample. In some of these examples, the biological sample is a sweat sample. In some of these examples, the biological sample is a tear sample. In some of these examples, the biological sample is a hair sample.


In some examples, including any of the foregoing, the method also includes digesting and/or fragmenting a glycopeptide in the sample. In certain examples, the method includes digesting a glycopeptide in the sample. In certain examples, the method includes fragmenting a glycopeptide in the sample. In some examples, the digested or fragmented glycopeptide is analyzed using mass spectroscopy. In some examples, the glycopeptide is digested or fragmented in the solution phase using digestive enzymes. In some examples, the glycopeptide is digested or fragmented in the gaseous phase inside a mass spectrometer, or the instrumentation associated with a mass spectrometer. In some examples, the mass spectroscopy results are analyzed using machine learning algorithms. In some examples, the mass spectroscopy results are the quantification of the glycopeptides, glycans, peptides, and fragments thereof. In some examples, this quantification is used as an input in a trained model to generate an output probability. The output probability is a probability of being within a given category or classification, e.g., the classification of having ovarian cancer or the classification of not having ovarian cancer. In some other examples, the output probability is a probability of being within a given category or classification, e.g., the classification of having cancer or the classification of not having cancer. In some other examples, the output probability is a probability of being within a given category or classification, e.g., the classification of having an autoimmune disease or the classification of not having an autoimmune disease. In some other examples, the output probability is a probability of being within a given category or classification, e.g., the classification of having fibrosis or the classification of not having an fibrosis.


In some examples, including any of the foregoing, the method includes introducing the sample, or a portion thereof, into a mass spectrometer.


In some examples, including any of the foregoing, the method includes fragmenting a glycopeptide in the sample after introducing the sample, or a portion thereof, into the mass spectrometer.


In some examples, including any of the foregoing, the mass spectroscopy is performed using multiple reaction monitoring (MRM) mode. In some examples, the mass spectroscopy is performed using QTOF MS in data-dependent acquisition. In some examples, the mass spectroscopy is performed using or MS-only mode. In some examples, an immunoassay is used in combination with mass spectroscopy. In some examples, the immunoassay measures CA-125 and HE4.


In some examples, including any of the foregoing, the method includes digesting a glycopeptide in the sample occurs before introducing the sample, or a portion thereof, into the mass spectrometer.


In some examples, including any of the foregoing, the method includes fragmenting a glycopeptide in the sample to provide a glycopeptide ion, a peptide ion, a glycan ion, a glycan adduct ion, or a glycan fragment ion.


In some examples, including any of the foregoing, the method includes digesting and/or fragmenting a glycopeptide in the sample to provide a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In some examples, the methods provides a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes digesting and/or fragmenting a glycopeptide in the sample to provide a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In some examples, the methods provides a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes digesting a glycopeptide in the sample to provide a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In some examples, the methods provides a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes digesting a glycopeptide in the sample to provide a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In some examples, the methods provides a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes fragmenting a glycopeptide in the sample to provide a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In some examples, the methods provides a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes fragmenting a glycopeptide in the sample to provide a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In some examples, the methods provides a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes detecting a multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide or glycan residue, wherein the glycopeptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 and combinations thereof. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 and combinations thereof. In some examples, the method includes detecting more than one MRM transition selected from a combination of members from the group consisting of transitions 1-150. In some examples, the method includes detecting more than one MRM transition indicative of a combination of glycopeptides having amino acid sequences selected from a combination of SEQ ID NOs: 1-262.


In some examples, the method includes detecting a MRM transition indicative of a glycopeptide or glycan residue, wherein the glycopeptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof. In some examples, the method includes detecting more than one MRM transition indicative of a combination of glycopeptides having amino acid sequences selected from a combination of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194.


In some examples, including any of the foregoing, the method includes performing mass spectroscopy on the biological sample using multiple-reaction-monitoring mass spectroscopy (MRM-MS).


In some examples, including any of the foregoing, the method includes digesting a glycopeptide in the sample to provide a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In certain examples, the biological sample is combined with chemical reagents. In certain examples, the biological sample is combined with enzymes. In some examples, the enzymes are lipases. In some examples, the enzymes are proteases. In some examples, the enzymes are serine proteases. In some of these examples, the enzyme is selected from the group consisting of trypsin, chymotrypsin, thrombin, elastase, and subtilisin. In some of these examples, the enzyme is trypsin. In some examples, the methods includes contacting at least two proteases with a glycopeptide in a sample. In some examples, the at least two proteases are selected from the group consisting of serine protease, threonine protease, cysteine protease, aspartate protease. In some examples, the at least two proteases are selected from the group consisting of trypsin, chymotrypsin, endoproteinase, Asp-N, Arg-C, Glu-C, Lys-C, pepsin, thermolysin, elastase, papain, proteinase K, subtilisin, clostripain, and carboxypeptidase protease, glutamic acid protease, metalloprotease, and asparagine peptide lyase.


In some examples, including any of the foregoing, the method includes detecting a multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide or glycan residue, wherein the glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 and combinations thereof. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide or glycan residue, wherein the glycopeptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 and combinations thereof. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 and combinations thereof. In some examples, the method includes detecting more than one MRM transition selected from a combination of members from the group consisting of transitions 1-262. In some examples, the method includes detecting more than one MRM transition indicative of a combination of glycopeptides having amino acid sequences selected from a combination of SEQ ID NOs: 1-262.


In some examples, the method includes detecting a MRM transition indicative of a glycopeptide or glycan residue, wherein the glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194 and combinations thereof. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide or glycan residue, wherein the glycopeptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194 and combinations thereof. In some examples, the method includes detecting a MRM transition indicative of a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof. In some examples, the method includes detecting more than one MRM transition selected from a combination of members from the group consisting of transitions 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194. In some examples, the method includes detecting more than one MRM transition indicative of a combination of glycopeptides having amino acid sequences selected from a combination of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, including any of the foregoing, the method includes performing mass spectroscopy on the biological sample using multiple-reaction-monitoring mass spectroscopy (MRM-MS).


In some examples, including any of the foregoing, the method includes digesting a glycopeptide in the sample to provide a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof. In certain examples, the biological sample is contacted with one or more chemical reagents. In certain examples, the biological sample is contacted with one or more enzymes. In some examples, the enzymes are lipases. In some examples, the enzymes are proteases. In some examples, the enzymes are serine proteases. In some of these examples, the enzyme is selected from the group consisting of trypsin, chymotrypsin, thrombin, elastase, and subtilisin. In some of these examples, the enzyme is trypsin. In some examples, the methods includes contacting at least two proteases with a glycopeptide in a sample. In some examples, the at least two proteases are selected from the group consisting of serine protease, threonine protease, cysteine protease, aspartate protease. In some examples, the at least two proteases are selected from the group consisting of trypsin, chymotrypsin, endoproteinase, Asp-N, Arg-C, Glu-C, Lys-C, pepsin, thermolysin, elastase, papain, proteinase K, subtilisin, clostripain, and carboxypeptidase protease, glutamic acid protease, metalloprotease, and asparagine peptide lyase.


In some examples, including any of the foregoing, the MRM transition is selected from the transitions, or any combinations thereof, in any one of Tables 1, 2 or 3.


In some examples, including any of the foregoing, the method includes conducting tandem liquid chromatography-mass spectroscopy on the biological sample.


In some examples, including any of the foregoing, the method includes multiple-reaction-monitoring mass spectroscopy (MRM-MS) mass spectroscopy on the biological sample.


In some examples, including any of the foregoing, the method includes detecting a MRM transition using a triple quadrupole (QQQ) and/or a quadrupole time-of-flight (qTOF) mass spectrometer. In certain examples, the method includes detecting a MRM transition using a QQQ mass spectrometer. In certain other examples, the method includes detecting using a qTOF mass spectrometer. In some examples, a suitable instrument for use with the instant methods is an Agilent 6495B Triple Quadrupole LC/MS, which can be found at www.agilent.com/en/products/mass-spectrometry/lc-ms-instruments/triple-quadrupole-lc-ms/6495b-triple-quadrupole-lc-ms. In certain other examples, the method includes detecting using a QQQ mass spectrometer. In some examples, a suitable instrument for use with the instant methods is an Agilent 6545 LC/Q-TOF, which can be found at https://www.agilent.com/en/products/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-instruments!quadrupole-time-of-flight-lc-ms/6545-q-tof-lc-ms.


In some examples, including any of the foregoing, the method includes detecting more than one MRM transition using a QQQ and/or qTOF mass spectrometer. In certain examples, the method includes detecting more than one MRM transition using a QQQ mass spectrometer. In certain examples, the method includes detecting more than one MRM transition using a qTOF mass spectrometer. In certain examples, the method includes detecting more than one MRM transition using a QQQ mass spectrometer.


In some examples, including any of the foregoing, the methods herein include quantifying one or more glycomic parameters of the one or more biological samples comprises employing a coupled chromatography procedure. In some examples, these glycomic parameters include the identification of a glycopeptide group, identification of glycans on the glycopeptide, identification of a glycosylation site, identification of part of an amino acid sequence which the glycopeptide includes. In some examples, the coupled chromatography procedure comprises: performing or effectuating a liquid chromatography-mass spectrometry (LC-MS) operation. In some examples, the coupled chromatography procedure comprises: performing or effectuating a multiple reaction monitoring mass spectrometry (MRM-MS) operation. In some examples, the methods herein include a coupled chromatography procedure which comprises: performing or effectuating a liquid chromatography-mass spectrometry (LC-MS) operation; and effectuating a multiple reaction monitoring mass spectrometry (MRM-MS) operation. In some examples, the methods include training a machine learning algorithm using one or more glycomic parameters of the one or more biological samples obtained by one or more of a triple quadrupole (QQQ) mass spectrometry operation and/or a quadrupole time-of-flight (qTOF) mass spectrometry operation. In some examples, the methods include training a machine learning algorithm using one or more glycomic parameters of the one or more biological samples obtained a triple quadrupole (QQQ) mass spectrometry operation. In some examples, the methods include training a machine learning algorithm using one or more glycomic parameters of the one or more biological samples obtained by a quadrupole time-of-flight (qTOF) mass spectrometry operation. In some examples, the methods include quantifying one or more glycomic parameters of the one or more biological samples comprises employing one or more of a triple quadrupole (QQQ) mass spectrometry operation and a quadrupole time-of-flight (qTOF) mass spectrometry operation. In some examples, machine learning algorithms are used to quantify these glycomic parameters. In some examples, including any of the foregoing, the mass spectroscopy is performed using multiple reaction monitoring (MRM) mode. In some examples, the mass spectroscopy is performed using QTOF MS in data-dependent acquisition. In some examples, the mass spectroscopy is performed using or MS-only mode. In some examples, an immunoassay (e.g., ELISA) is used in combination with mass spectroscopy. In some examples, the immunoassay measures CA-125 and HE4 proteins.


In some examples, including any of the foregoing, the glycopeptide or combination thereof consists of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 and combinations thereof.


In some examples, including any of the foregoing, the glycopeptide or combination thereof consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 and combinations thereof.


In some examples, including any of the foregoing, the method includes digesting and/or fragmenting a glycopeptide in the sample to provide a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 and combinations thereof.


In some examples, including any of the foregoing, the method includes digesting and/or fragmenting a glycopeptide in the sample to provide a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 and combinations thereof.


In some examples, including any of the foregoing, the glycopeptide or combination thereof consists of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the glycopeptide or combination thereof consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes digesting and/or fragmenting a glycopeptide in the sample to provide a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes digesting and/or fragmenting a glycopeptide in the sample to provide a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes detecting one or more MRM transitions indicative of glycans selected from the group consisting of glycan 3200, 3210, 3300, 3310, 3320, 3400, 3410, 3420, 3500, 3510, 3520, 3600, 3610, 3620, 3630, 3700, 3710, 3720, 3730, 3740, 4200, 4210, 4300, 4301, 4310, 4311, 4320, 4400, 4401, 4410, 4411, 4420, 4421, 4430, 4431, 4500, 4501, 4510, 4511, 4520, 4521, 4530, 4531, 4540, 4541, 4600, 4601, 4610, 4611, 4620, 4621, 4630, 4631, 4641, 4650, 4700, 4701, 4710, 4711, 4720, 4730, 5200, 5210, 5300, 5301, 5310, 5311, 5320, 5400, 5401, 5402, 5410, 5411, 5412, 5420, 5421, 5430, 5431, 5432, 5500, 5501, 5502, 5510, 5511, 5512, 5520, 5521, 5522, 5530, 5531, 5541, 5600, 5601, 5602, 5610, 5611, 5612, 5620, 5621, 5631, 5650, 5700, 5701, 5702, 5710, 5711, 5712, 5720, 5721, 5730, 5731, 6200, 6210, 6300, 6301, 6310, 6311, 6320, 6400, 6401, 6402, 6410, 6411, 6412, 6420, 6421, 6432, 6500, 6501, 6502, 6503, 6510, 6511, 6512, 6513, 6520, 6521, 6522, 6530, 6531, 6532, 6540, 6541, 6600, 6601, 6602, 6603, 6610, 6611, 6612, 6613, 6620, 6621, 6622, 6623, 6630, 6631, 6632, 6640, 6641, 6642, 6652, 6700, 6701, 6711, 6721, 6703, 6713, 6710, 6711, 6712, 6713, 6720, 6721, 6730, 6731, 6740, 7200, 7210, 7400, 7401, 7410, 7411, 7412, 7420, 7421, 7430, 7431, 7432, 7500, 7501, 7510, 7511, 7512, 7600, 7601, 7602, 7603, 7604, 7610, 7611, 7612, 7613, 7614, 7620, 7621, 7622, 7623, 7632, 7640, 7700, 7701, 7702, 7703, 7710, 7711, 7712, 7713, 7714, 7720, 7721, 7722, 7730, 7731, 7732, 7740, 7741, 7751, 8200, 9200, 9210, 10200, 11200, 12200, and combinations thereof. Herein, these glycans are illustrated in FIGS. 1-14.


In some examples, including any of the foregoing, the method includes quantifying a glycan.


In some examples, including any of the foregoing, the method includes quantifying a first glycan and quantifying a second glycan; and further comprising comparing the quantification of the first glycan with the quantification of the second glycan.


In some examples, including any of the foregoing, the method includes associating the detected glycan with a peptide residue site, whence the glycan was bonded.


In some examples, including any of the foregoing, the method includes generating a glycosylation profile of the sample.


In some examples, including any of the foregoing, the method includes spatially profiling glycans on a tissue section associated with the sample. In some examples, including any of the foregoing, the method includes spatially profiling glycopeptides on a tissue section associated with the sample. In some examples, the method includes matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) mass spectroscopy in combination with the methods herein.


In some examples, including any of the foregoing, the method includes quantifying relative abundance of a glycan and/or a peptide.


In some examples, including any of the foregoing, the method includes normalizing the amount of a glycopeptide by quantifying a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof and comparing that quantification to the amount of another chemical species. In some examples, the method includes normalizing the amount of a peptide by quantifying a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof, and comparing that quantification to the amount of another glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262. In some examples, the method includes normalizing the amount of a peptide by quantifying a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof, and comparing that quantification to the amount of another glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


B. Methods for Classifying Samples Comprising Glycopeptides


In another embodiment, set forth herein a method for identifying a classification for a sample, the method comprising: quantifying by mass spectroscopy (MS) one or more glycopeptides in a sample wherein the glycopeptides each, individually in each instance, comprises a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of, or consisting essentially of, SEQ ID NOs:1-262, and combinations thereof, and inputting the quantification into a trained model to generate a output probability; determining if the output probability is above or below a threshold for a classification; and identifying a classification for the sample based on whether the output probability is above or below a threshold for a classification.


In another embodiment, set forth herein a method for identifying a classification for a sample, the method comprising: quantifying by mass spectroscopy (MS) one or more glycopeptides in a sample wherein the glycopeptides each, individually in each instance, comprises a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of, or consisting essentially of, SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof; and inputting the quantification into a trained model to generate a output probability; determining if the output probability is above or below a threshold for a classification; and identifying a classification for the sample based on whether the output probability is above or below a threshold for a classification.


In some examples, set forth herein is a method for classifying glycopeptides, comprising: obtaining a biological sample from a patient; digesting and/or fragmenting a glycopeptide in the sample; detecting a multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150; and classifying the glycopeptides based on the MRM transitions detected. In some examples, a machine learning algorithm is used to train a model using the analyzed the MRM transitions as inputs. In some examples, a machine learning algorithm is trained using the MRM transitions as a training data set. In some examples, the methods herein include identifying glycopeptides, peptides, and glycans based on their mass spectroscopy relative abundance. In some examples, a machine learning algorithm or algorithms select and/or identify peaks in a mass spectroscopy spectrum.


In some examples, set forth herein is a method for classifying glycopeptides, comprising: obtaining a biological sample from an individual; digesting and/or fragmenting a glycopeptide in the sample; detecting a multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150; and classifying the glycopeptides based on the MRM transitions detected. In some examples, a machine learning algorithm is used to train a model using the analyzed the MRM transitions as inputs. In some examples, a machine learning algorithm is trained using the MRM transitions as a training data set. In some examples, the methods herein include identifying glycopeptides, peptides, and glycans based on their mass spectroscopy relative abundance. In some examples, a machine learning algorithm or algorithms select and/or identify peaks in a mass spectroscopy spectrum.


In some examples, set forth herein is a method of training a machine learning algorithm using MRM transitions as an input data set. In some examples, set forth herein is a method for identifying a classification for a sample, the method comprising quantifying by mass spectroscopy (MS) a glycopeptide in a sample wherein the glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof; and identifying a classification based on the quantification. In some examples, the quantifying includes determining the presence or absence of a glycopeptide, or combination of glycopeptides, in a sample. In some examples, the quantifying includes determining the relative abundance of a glycopeptide, or combination of glycopeptides, in a sample.


In some examples, set forth herein is a method of training a machine learning algorithm using MRM transitions as an input data set. In some examples, set forth herein is a method for identifying a classification for a sample, the method comprising quantifying by mass spectroscopy (MS) a glycopeptide in a sample wherein the glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof; and identifying a classification based on the quantification. In some examples, the quantifying includes determining the presence or absence of a glycopeptide, or combination of glycopeptides, in a sample. In some examples, the quantifying includes determining the relative abundance of a glycopeptide, or combination of glycopeptides, in a sample.


In some examples, including any of the foregoing, the sample is a biological sample from a patient having a disease or condition.


In some examples, including any of the foregoing, the patient has ovarian cancer.


In some examples, including any of the foregoing, the patient has cancer.


In some examples, including any of the foregoing, the patient has fibrosis.


In some examples, including any of the foregoing, the patient has an autoimmune disease.


In some examples, including any of the foregoing, the disease or condition is ovarian cancer.


In some examples, including any of the foregoing, the MS is MRM-MS with a QQQ and/or qTOF mass spectrometer.


In some examples, including any of the foregoing, the mass spectroscopy is performed using multiple reaction monitoring (MRM) mode. In some examples, the mass spectroscopy is performed using QTOF MS in data-dependent acquisition. In some examples, the mass spectroscopy is performed using or MS-only mode. In some examples, an immunoassay is used in combination with mass spectroscopy. In some examples, the immunoassay measures CA-125 and HE4.


In some examples, including any of the foregoing, the machine learning algorithm is selected from the group consisting of a deep learning algorithm, a neural network algorithm, an artificial neural network algorithm, a supervised machine learning algorithm, a linear discriminant analysis algorithm, a quadratic discriminant analysis algorithm, a support vector machine algorithm, a linear basis function kernel support vector algorithm, a radial basis function kernel support vector algorithm, a random forest algorithm, a genetic algorithm, a nearest neighbor algorithm, k-nearest neighbors, a naive Bayes classifier algorithm, a logistic regression algorithm, or a combination thereof. In certain examples, the machine learning algorithm is lasso regression.


In some examples, including any of the foregoing, the method includes classifying a sample as within, or embraced by, a disease classification or a disease severity classification.


In some examples, including any of the foregoing, the classification is identified with 80% confidence, 85% confidence, 90% confidence, 95% confidence, 99% confidence, or 99.9999% confidence.


In some examples, including any of the foregoing, the method includes quantifying by MS the glycopeptide in a sample at a first time point; quantifying by MS the glycopeptide in a sample at a second time point; and comparing the quantification at the first time point with the quantification at the second time point.


In some examples, including any of the foregoing, the method includes quantifying by MS a different glycopeptide in a sample at a third time point; quantifying by MS the different glycopeptide in a sample at a fourth time point; and comparing the quantification at the fourth time point with the quantification at the third time point.


In some examples, including any of the foregoing, the method includes monitoring the health status of a patient.


In some examples, including any of the foregoing, monitoring the health status of a patient includes monitoring the onset and progression of disease in a patient with risk factors such as genetic mutations, as well as detecting cancer recurrence.


In some examples, including any of the foregoing, the method includes quantifying by MS a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, the method includes quantifying by MS a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, the method includes quantifying by MS one or more glycans selected from the group consisting of glycan 3200, 3210, 3300, 3310, 3320, 3400, 3410, 3420, 3500, 3510, 3520, 3600, 3610, 3620, 3630, 3700, 3710, 3720, 3730, 3740, 4200, 4210, 4300, 4301, 4310, 4311, 4320, 4400, 4401, 4410, 4411, 4420, 4421, 4430, 4431, 4500, 4501, 4510, 4511, 4520, 4521, 4530, 4531, 4540, 4541, 4600, 4601, 4610, 4611, 4620, 4621, 4630, 4631, 4641, 4650, 4700, 4701, 4710, 4711, 4720, 4730, 5200, 5210, 5300, 5301, 5310, 5311, 5320, 5400, 5401, 5402, 5410, 5411, 5412, 5420, 5421, 5430, 5431, 5432, 5500, 5501, 5502, 5510, 5511, 5512, 5520, 5521, 5522, 5530, 5531, 5541, 5600, 5601, 5602, 5610, 5611, 5612, 5620, 5621, 5631, 5650, 5700, 5701, 5702, 5710, 5711, 5712, 5720, 5721, 5730, 5731, 6200, 6210, 6300, 6301, 6310, 6311, 6320, 6400, 6401, 6402, 6410, 6411, 6412, 6420, 6421, 6432, 6500, 6501, 6502, 6503, 6510, 6511, 6512, 6513, 6520, 6521, 6522, 6530, 6531, 6532, 6540, 6541, 6600, 6601, 6602, 6603, 6610, 6611, 6612, 6613, 6620, 6621, 6622, 6623, 6630, 6631, 6632, 6640, 6641, 6642, 6652, 6700, 6701, 6711, 6721, 6703, 6713, 6710, 6711, 6712, 6713, 6720, 6721, 6730, 6731, 6740, 7200, 7210, 7400, 7401, 7410, 7411, 7412, 7420, 7421, 7430, 7431, 7432, 7500, 7501, 7510, 7511, 7512, 7600, 7601, 7602, 7603, 7604, 7610, 7611, 7612, 7613, 7614, 7620, 7621, 7622, 7623, 7632, 7640, 7700, 7701, 7702, 7703, 7710, 7711, 7712, 7713, 7714, 7720, 7721, 7722, 7730, 7731, 7732, 7740, 7741, 7751, 8200, 9200, 9210, 10200, 11200, 12200, and combinations thereof. Herein, these glycans are illustrated in FIGS. 1-14.


In some examples, including any of the foregoing, the method includes diagnosing a patient with a disease or condition based on the quantification.


In some examples, including any of the foregoing, the method includes diagnosing the patient as having ovarian cancer based on the quantification.


In some examples, including any of the foregoing, the method includes treating the patient with a therapeutically effective amount of a therapeutic agent selected from the group consisting of a chemotherapeutic, an immunotherapy, a hormone therapy, a targeted therapy, a neoadjuvant therapy, surgery, and combinations thereof.


In some examples, including any of the foregoing, the method includes diagnosing an individual with a disease or condition based on the quantification.


In some examples, including any of the foregoing, the method includes diagnosing the individual as having an aging condition.


In some examples, including any of the foregoing, the method includes treating the individual with a therapeutically effective amount of an anti-aging agent. In some examples, the anti-aging agent is selected from hormone therapy. In some examples, the anti-aging agent is testosterone or a testosterone supplement or derivative. In some examples, the anti-aging agent is estrogen or an estrogen supplement or derivative.


C. Methods of Treatment


In some examples, set forth herein is a method for treating a patient having a disease or condition, comprising measuring by mass spectroscopy a glycopeptide in a sample from the patient. In some examples, the patient is a human. In certain examples, the patient is a female. In certain other examples, the patient is a female with ovarian cancer. In certain examples, the patient is a female with ovarian cancer at Stage 1. In certain examples, the patient is a female with ovarian cancer at Stage 2. In certain examples, the patient is a female with ovarian cancer at Stage 3. In certain examples, the patient is a female with ovarian cancer at Stage 4. In some examples, the female has an age equal or between 10-20 years. In some examples, the female has an age equal or between 20-30 years. In some examples, the female has an age equal or between 30-40 years. In some examples, the female has an age equal or between 40-50 years. In some examples, the female has an age equal or between 50-60 years. In some examples, the female has an age equal or between 60-70 years. In some examples, the female has an age equal or between 70-80 years. In some examples, the female has an age equal or between 80-90 years. In some examples, the female has an age equal or between 90-100 years.


In another embodiment, set forth herein is a method for treating a patient having ovarian cancer; the method comprising: obtaining a biological sample from the patient; digesting and/or fragmenting one or more glycopeptides in the sample; and detecting and quantifying one or more multiple-reaction-monitoring (MRM) transitions selected from the group consisting of transitions 1-150; inputting the quantification into a trained model to generate an output probability; determining if the output probability is above or below a threshold for a classification; and classifying the patient based on whether the output probability is above or below a threshold for a classification, wherein the classification is selected from the group consisting of (A) a patient in need of a chemotherapeutic agent; (B) a patient in need of a immunotherapeutic agent; (C) a patient in need of hormone therapy; (D) a patient in need of a targeted therapeutic agent; (E) a patient in need of surgery; (F) a patient in need of neoadjuvant therapy; (G) a patient in need of chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof, before surgery; (H) a patient in need of chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof, after surgery; (I) or a combination thereof; administering a therapeutically effective amount of a therapeutic agent to the patient: wherein the therapeutic agent is selected from chemotherapy if classification A or I is determined; wherein the therapeutic agent is selected from immunotherapy if classification B or I is determined; or wherein the therapeutic agent is selected from hormone therapy if classification C or I is determined; or wherein the therapeutic agent is selected from targeted therapy if classification D or I is determined wherein the therapeutic agent is selected from neoadjuvant therapy if classification F or I is determined; wherein the therapeutic agent is selected from chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof if classification G or I is determined; and wherein the therapeutic agent is selected from chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof if classification H or I is determined.


In some examples, the machine learning is used to identify MS peaks associated with MRM transitions. In some examples, the MRM transitions are analyzed using machine learning. In some examples, the machine learning is used to train a model based on the quantification of the amount of glycopeptides associated with an MRM transition(s). In some examples, the MRM transitions are analyzed with a trained machine learning algorithm. In some of these examples, the trained machine learning algorithm was trained using MRM transitions observed by analyzing samples from patients known to have ovarian cancer.


In some examples, the patient is treated with a therapeutic agent selected from targeted therapy. In some examples, the methods herein include administering a therapeutically effective amount of a (poly(ADP)-ribose polymerase) (PARP) inhibitor if combination D is detected. In some examples, the therapeutic agent is selected from Olaparib (Lynparza), Rucaparib (Rubraca), and Niraparib (Zejula).


In some examples, the patient is an adult with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.


In some examples, the therapeutic agent is administered at 150 mg, 250 mg, 300 mg, 350 mg, and 600 mg doses. In some examples, the therapeutic agent is administered twice daily.


Chemotherapeutic agents include, but are not limited to, platinum-based drug such as carboplatin (Paraplatin) or cisplatin with a taxane such as paclitaxel (Taxol) or docetaxel (Taxotere). Paraplatin may be administered at 10 mg/mL injectable concentrations (in vials of 50, 150, 450, and 600 mg). For advanced ovarian carcinoma a single agent dose of 360 mg/m2 IV for 4 weeks may be administered. Paraplatin may be administered in combination=as 300 mg/m2 IV (plus cyclophosphamide 600 mg/m2 IV) q4Weeks. Taxol may be administered at 175 mg/m2 IV over 3 hours q3Weeks (follow with cisplatin). Taxol may be administered at 135 mg/m2 IV over 24 hours q3Weeks (follow with cisplatin). Taxol may be administered at 135-175 mg/m2 IV over 3 hours q3Weeks.


Immunotherapeutic agents include, but are not limited to, Zejula (Niraparib). Niraparib may be administered at 300 mg PO qDay.


Hormone therapeutic agents include, but are not limited to, Luteinizing-hormone-releasing hormone (LHRH) agonists, Tamoxifen, and Aromatase inhibitors.


Targeted therapeutic agents include, but are not limited to, PARP inhibitors.


In some examples, including any of the foregoing, the method includes conducting multiple-reaction-monitoring mass spectroscopy (MRM-MS) on the biological sample.


In some examples, including any of the foregoing, the mass spectroscopy is performed using multiple reaction monitoring (MRM) mode. In some examples, the mass spectroscopy is performed using QTOF MS in data-dependent acquisition. In some examples, the mass spectroscopy is performed using or MS-only mode. In some examples, an immunoassay (e.g., ELISA) is used in combination with mass spectroscopy. In some examples, the immunoassay measures CA-125 and HE4.


In some examples, including any of the foregoing, the method includes quantifying one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 and combinations thereof.


In some examples, including any of the foregoing, the method includes quantifying one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 and combinations thereof.


In some examples, including any of the foregoing, the method includes quantifying one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes quantifying one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method includes detecting a multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150 using a QQQ and/or a qTOF mass spectrometer.


In some examples, including any of the foregoing, the method includes training a machine learning algorithm to identify a classification based on the quantifying step.


In some examples, including any of the foregoing, the method includes using a machine learning algorithm to identify a classification based on the quantifying step.


In some examples, including any of the foregoing, the machine learning algorithm is selected from the group consisting of a deep learning algorithm, a neural network algorithm, an artificial neural network algorithm, a supervised machine learning algorithm, a linear discriminant analysis algorithm, a quadratic discriminant analysis algorithm, a support vector machine algorithm, a linear basis function kernel support vector algorithm, a radial basis function kernel support vector algorithm, a random forest algorithm, a genetic algorithm, a nearest neighbor algorithm, k-nearest neighbors, a naive Bayes classifier algorithm, a logistic regression algorithm, or a combination thereof.


D. Methods for Diagnosing Patients


In some examples, set forth herein is a method for diagnosing a patient having a disease or condition, comprising measuring by mass spectroscopy a glycopeptide in a sample from the patient.


In another embodiment, set forth herein is a method for diagnosing a patient having ovarian cancer; the method comprising: obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect and quantify one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262; or to detect and quantify one or more MRM transitions selected from transitions 1-150; inputting the quantification of the detected glycopeptides or the MRM transitions into a trained model to generate an output probability, determining if the output probability is above or below a threshold for a classification; and identifying a diagnostic classification for the patient based on whether the output probability is above or below a threshold for a classification; and diagnosing the patient as having ovarian cancer based on the diagnostic classification.


In another embodiment, set forth herein is a method for diagnosing a patient having ovarian cancer; the method comprising: inputting the quantification of detected glycopeptides or MRM transitions into a trained model to generate an output probability, determining if the output probability is above or below a threshold for a classification; and identifying a diagnostic classification for the patient based on whether the output probability is above or below a threshold for a classification; and diagnosing the patient as having ovarian cancer based on the diagnostic classification. In some examples, the method includes obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect and quantify one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262; or to detect and quantify one or more MRM transitions selected from transitions 1-150.


In some examples, set forth herein is a method for diagnosing a patient having ovarian cancer; the method comprising: obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect one or more glycopeptides consisting or, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262; or to detect one or more MRM transitions selected from transitions 1-150; analyzing the detected glycopeptides or the MRM transitions to identify a diagnostic classification; and diagnosing the patient as having ovarian cancer based on the diagnostic classification. In some examples, the method includes obtaining a biological sample from the patient; and performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect one or more glycopeptides consisting or, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-76; or to detect one or more MRM transitions selected from transitions 1-76.


In some examples, set forth herein is a method for diagnosing, monitoring, or classifying aging in an individual; the method comprising: obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect one or more glycopeptides consisting or, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262; or to detect one or more MRM transitions selected from transitions 1-150; analyzing the detected glycopeptides or the MRM transitions to identify a diagnostic classification; and diagnosing, monitoring, or classifying the individual as having an aging classification based on the diagnostic classification.


In another embodiment, set forth herein is a method for diagnosing a patient having ovarian cancer; the method comprising: obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect and quantify one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194; inputting the quantification of the detected glycopeptides or the MRM transitions into a trained model to generate an output probability, determining if the output probability is above or below a threshold for a classification; and identifying a diagnostic classification for the patient based on whether the output probability is above or below a threshold for a classification; and diagnosing the patient as having ovarian cancer based on the diagnostic classification.


In some examples, set forth herein is a method for diagnosing a patient having ovarian cancer; the method comprising: obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect one or more glycopeptides consisting or, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194; analyzing the detected glycopeptides or the MRM transitions to identify a diagnostic classification; and diagnosing the patient as having ovarian cancer based on the diagnostic classification.


In some examples, set forth herein is a method for diagnosing, monitoring, or classifying aging in an individual; the method comprising: obtaining a biological sample from the patient; performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect one or more glycopeptides consisting or, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194; analyzing the detected glycopeptides or the MRM transitions to identify a diagnostic classification; and diagnosing, monitoring, or classifying the individual as having an aging classification based on the diagnostic classification.


E. Diseases and Conditions


Set forth herein are biomarkers for diagnosing a variety of diseases and conditions.


In some examples, the diseases and conditions include cancer. In some examples, the diseases and conditions are not limited to cancer.


In some examples, the diseases and conditions include fibrosis. In some examples, the diseases and conditions are not limited to fibrosis.


In some examples, the diseases and conditions include an autoimmune disease. In some examples, the diseases and conditions are not limited to an autoimmune disease.


In some examples, the diseases and conditions include ovarian cancer. In some examples, the diseases and conditions are not limited to ovarian cancer.


In some examples, the condition is aging. In some examples, the “patient” described herein is equivalently described as an “individual.” For example, in some methods herein, set forth are biomarkers for monitoring or diagnosing aging or aging conditions in an individual. In some of these examples, the individual is not necessarily a patient who has a medical condition in need of therapy. In some examples, the individual is a male. In some examples, the individual is a female. In some examples, the individual is a male mammal. In some examples, the individual is a female mammal. In some examples, the individual is a male human. In some examples, the individual is a female human.


In some examples, the individual is 1 year old. In some examples, the individual is 2 years old. In some examples, the individual is 3 years old. In some examples, the individual is 4 years old. In some examples, the individual is 5 years old. In some examples, the individual is 6 years old. In some examples, the individual is 7 years old. In some examples, the individual is 8 years old. In some examples, the individual is 9 years old. In some examples, the individual is 10 years old. In some examples, the individual is 11 years old. In some examples, the individual is 12 years old. In some examples, the individual is 13 years old. In some examples, the individual is 14 years old. In some examples, the individual is 15 years old. In some examples, the individual is 16 years old. In some examples, the individual is 17 years old. In some examples, the individual is 18 years old. In some examples, the individual is 19 years old. In some examples, the individual is 20 years old. In some examples, the individual is 21 years old. In some examples, the individual is 22 years old. In some examples, the individual is 23 years old. In some examples, the individual is 24 years old. In some examples, the individual is 25 years old. In some examples, the individual is 26 years old. In some examples, the individual is 27 years old. In some examples, the individual is 28 years old. In some examples, the individual is 29 years old. In some examples, the individual is 30 years old. In some examples, the individual is 31 years old. In some examples, the individual is 32 years old. In some examples, the individual is 33 years old. In some examples, the individual is 34 years old. In some examples, the individual is 35 years old. In some examples, the individual is 36 years old. In some examples, the individual is 37 years old. In some examples, the individual is 38 years old. In some examples, the individual is 39 years old. In some examples, the individual is 40 years old. In some examples, the individual is 41 years old. In some examples, the individual is 42 years old. In some examples, the individual is 43 years old. In some examples, the individual is 44 years old. In some examples, the individual is 45 years old. In some examples, the individual is 46 years old. In some examples, the individual is 47 years old. In some examples, the individual is 48 years old. In some examples, the individual is 49 years old. In some examples, the individual is 50 years old. In some examples, the individual is 51 years old. In some examples, the individual is 52 years old. In some examples, the individual is 53 years old. In some examples, the individual is 54 years old. In some examples, the individual is 55 years old. In some examples, the individual is 56 years old. In some examples, the individual is 57 years old. In some examples, the individual is 58 years old. In some examples, the individual is 59 years old. In some examples, the individual is 60 years old. In some examples, the individual is 61 years old. In some examples, the individual is 62 years old. In some examples, the individual is 63 years old. In some examples, the individual is 64 years old. In some examples, the individual is 65 years old. In some examples, the individual is 66 years old. In some examples, the individual is 67 years old. In some examples, the individual is 68 years old. In some examples, the individual is 69 years old. In some examples, the individual is 70 years old. In some examples, the individual is 71 years old. In some examples, the individual is 72 years old. In some examples, the individual is 73 years old. In some examples, the individual is 74 years old. In some examples, the individual is 75 years old. In some examples, the individual is 76 years old. In some examples, the individual is 77 years old. In some examples, the individual is 78 years old. In some examples, the individual is 79 years old. In some examples, the individual is 80 years old. In some examples, the individual is 81 years old. In some examples, the individual is 82 years old. In some examples, the individual is 83 years old. In some examples, the individual is 84 years old. In some examples, the individual is 85 years old. In some examples, the individual is 86 years old. In some examples, the individual is 87 years old. In some examples, the individual is 88 years old. In some examples, the individual is 89 years old. In some examples, the individual is 90 years old. In some examples, the individual is 91 years old. In some examples, the individual is 92 years old. In some examples, the individual is 93 years old. In some examples, the individual is 94 years old. In some examples, the individual is 95 years old. In some examples, the individual is 96 years old. In some examples, the individual is 97 years old. In some examples, the individual is 98 years old. In some examples, the individual is 99 years old. In some examples, the individual is 100 years old. In some examples, the individual is more than 100 years old.


V. MACHINE LEARNING

In some examples, including any of the foregoing, the methods herein include quantifying one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 using mass spectroscopy and/or liquid chromatography. In some examples, the methods includes quantifying one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof using mass spectroscopy and/or liquid chromatography. In some examples, the quantification results are used as inputs in a trained model. In some examples, the quantification results are classified or categorized with a diagnostic algorithm based on the absolute amount, relative amount, and/or type of each glycan or glycopeptide quantified in the test sample, wherein the diagnostic algorithm is trained on corresponding values for each marker obtained from a population of individuals having known diseases or conditions. In some examples, the disease or condition is ovarian cancer.


In some examples, including any of the foregoing, set forth herein is a method for training a machine learning algorithm, comprising: providing a first data set of MRM transition signals indicative of a sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262; providing a second data set of MRM transition signals indicative of a control sample; and comparing the first data set with the second data set using a machine learning algorithm. In some examples, the methods include providing a first data set of MRM transition signals indicative of a sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.


In some examples, including any of the foregoing, the method herein include using a sample comprising a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 is a sample from a patient having ovarian cancer.


In some examples, including any of the foregoing, the method herein include using a sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 is a sample from a patient having ovarian cancer.


In some examples, including any of the foregoing, the method herein include using a sample comprising a glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof is a sample from a patient having ovarian cancer.


In some examples, including any of the foregoing, the method herein include using a sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof is a sample from a patient having ovarian cancer.


In some examples, including any of the foregoing, the method herein include using a control sample, wherein the control sample is a sample from a patient not having ovarian cancer.


In some examples, including any of the foregoing, the method herein include using a sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262, which is a pooled sample from one or more patients having ovarian cancer.


In some examples, including any of the foregoing, the method herein include using a sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof, which is a pooled sample from one or more patients having ovarian cancer.


In some examples, including any of the foregoing, the method herein include using a control sample, which is a pooled sample from one or more patients not having ovarian cancer.


In some examples, including any of the foregoing, the methods include generating machine learning models trained using mass spectrometry data (e.g., MRM-MS transition signals) from patients having a disease or condition and patients not having a disease or condition. In some examples, the disease or condition is ovarian cancer. In some examples, the methods include optimizing the machine learning models by cross-validation with known standards or other samples. In some examples, the methods include qualifying the performance using the mass spectrometry data to form panels of glycans and glycopeptides with individual sensitivities and specificities. In certain examples, the methods include determining a confidence percent in relation to a diagnosis. In some examples, one to ten glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 may be useful for diagnosing a patient with ovarian cancer with a certain confidence percent. In some examples, ten to fifty glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 may be useful for diagnosing a patient with ovarian cancer with a higher confidence percent.


In some examples, including any of the foregoing, the methods include performing MRM-MS and/or LC-MS on a biological sample. In some examples, the methods include constructing, by a computing device, theoretical mass spectra data representing a plurality of mass spectra, wherein each of the plurality of mass spectra corresponds to one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262. In some examples, the methods include comparing, by the computing device, the mass spectra data with the theoretical mass spectra data to generate comparison data indicative of a similarity of each of the plurality of mass spectra to each of the plurality of theoretical target mass spectra associated with a corresponding glycopeptide of the plurality of glycopeptides.


In some examples, including any of the foregoing, the methods include generating machine learning models trained using mass spectrometry data (e.g., MRM-MS transition signals) from patients having a disease or condition and patients not having a disease or condition. In some examples, the disease or condition is ovarian cancer. In some examples, the methods include optimizing the machine learning models by cross-validation with known standards or other samples. In some examples, the methods include qualifying the performance using the mass spectrometry data to form panels of glycans and glycopeptides with individual sensitivities and specificities. In certain examples, the methods include determining a confidence percent in relation to a diagnosis. In some examples, one to ten glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 may be useful for diagnosing a patient with ovarian cancer with a certain confidence percent. In some examples, ten to fifty glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 may be useful for diagnosing a patient with ovarian cancer with a higher confidence percent.


In some examples, including any of the foregoing, the methods include performing MRM-MS and/or LC-MS on a biological sample. In some examples, the methods include constructing, by a computing device, theoretical mass spectra data representing a plurality of mass spectra, wherein each of the plurality of mass spectra corresponds to one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194. In some examples, the methods include comparing, by the computing device, the mass spectra data with the theoretical mass spectra data to generate comparison data indicative of a similarity of each of the plurality of mass spectra to each of the plurality of theoretical target mass spectra associated with a corresponding glycopeptide of the plurality of glycopeptides.


In some examples, machine learning algorithms are used to determine, by the computing device and based on the MRM-MS data, a distribution of a plurality of characteristic ions in the plurality of mass spectra; and determining, by the computing device and based on the distribution, whether one or more of the plurality of characteristic ions is a glycopeptide ion.


In some examples, the methods herein include training a diagnostic algorithm. Herein, training the diagnostic algorithm may refer to supervised learning of a diagnostic algorithm on the basis of values for one or more glycopeptides consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262. Training the diagnostic algorithm may refer to variable selection in a statistical model on the basis of values for one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262. Training a diagnostic algorithm may for example include determining a weighting vector in feature space for each category, or determining a function or function parameters.


In some examples, the methods herein include training a diagnostic algorithm. Herein, training the diagnostic algorithm may refer to supervised learning of a diagnostic algorithm on the basis of values for one or more glycopeptides consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof. Training the diagnostic algorithm may refer to variable selection in a statistical model on the basis of values for one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof. Training a diagnostic algorithm may for example include determining a weighting vector in feature space for each category, or determining a function or function parameters.


In some examples, including any of the foregoing, the machine learning algorithm is selected from the group consisting of a deep learning algorithm, a neural network algorithm, an artificial neural network algorithm, a supervised machine learning algorithm, a linear discriminant analysis algorithm, a quadratic discriminant analysis algorithm, a support vector machine algorithm, a linear basis function kernel support vector algorithm, a radial basis function kernel support vector algorithm, a random forest algorithm, a genetic algorithm, a nearest neighbor algorithm, k-nearest neighbors, a naive Bayes classifier algorithm, a logistic regression algorithm, or a combination thereof. In certain examples, the machine learning algorithm is lasso regression.


In certain examples, the machine learning algorithm is LASSO, Ridge Regression, Random Forests, K-nearest Neighbors (KNN), Deep Neural Networks (DNN), and Principal Components Analysis (PCA). In certain examples, DNN's are used to process mass spec data into analysis-ready forms. In some examples, DNN's are used for peak picking from a mass spectra. In some examples, PCA is useful in feature detection.


In some examples, LASSO is used to provide feature selection.


In some examples, machine learning algorithms are used to quantify peptides from each protein that are representative of the protein abundance. In some examples, this quantification includes quantifying proteins for which glycosylation is not measured.


In some examples, glycopeptide sequences are identified by fragmentation in the mass spectrometer and database search using Byonic software.


In some examples, the methods herein include unsupervised learning to detect features of MRMS-MS data that represent known biological quantities, such as protein function or glycan motifs. In certain examples, these features are used as input for classifying by machine. In some examples, the classification is performed using LASSO, Ridge Regression, or Random Forest nature.


In some examples, the methods herein include mapping input data (e.g., MRM transition peaks) to a value (e.g., a scale based on 0-100) before processing the value in an algorithm. For example, after a MRM transition is identified and the peak characterized, the methods herein include assessing the MS scans in an m/z and retention time window around the peak for a given patient. In some examples, the resulting chromatogram is integrated by a machine learning algorithm that determines the peak start and stop points, and calculates the area bounded by those points and the intensity (height). The resulting integrated value is the abundance, which then feeds into machine learning and statistical analyses training and data sets.


In some examples, machine learning output, in one instance, is used as machine learning input in another instance. For example, in addition to the PCA being used for a classification process, the DNN data processing feeds into PCA and other analyses. This results in at least three levels of algorithmic processing. Other hierarchical structures are contemplated within the scope of the instant disclosure.


In some examples, including any of the foregoing, the methods include comparing the amount of each glycan or glycopeptide quantified in the sample to corresponding reference values for each glycan or glycopeptide in a diagnostic algorithm. In some examples, the methods includes a comparative process by which the amount of a glycan or glycopeptide quantified in the sample is compared to a reference value for the same glycan or glycopeptide using a diagnostic algorithm. The comparative process may be part of a classification by a diagnostic algorithm. The comparative process may occur at an abstract level, e.g., in n-dimensional feature space or in a higher dimensional space.


In some examples, the methods herein include classifying a patient's sample based on the amount of each glycan or glycopeptide quantified in the sample with a diagnostic algorithm. In some examples, the methods include using statistical or machine learning classification processes by which the amount of a glycan or glycopeptide quantified in the test sample is used to determine a category of health with a diagnostic algorithm. In some examples, the diagnostic algorithm is a statistical or machine learning classification algorithm.


In some examples, including any of the foregoing, classification by a diagnostic algorithm may include scoring likelihood of a panel of glycan or glycopeptide values belonging to each possible category, and determining the highest-scoring category. Classification by a diagnostic algorithm may include comparing a panel of marker values to previous observations by means of a distance function. Examples of diagnostic algorithms suitable for classification include random forests, support vector machines, logistic regression (e.g. multiclass or multinomial logistic regression, and/or algorithms adapted for sparse logistic regression). A wide variety of other diagnostic algorithms that are suitable for classification may be used, as known to a person skilled in the art.


In some examples, the methods herein include supervised learning of a diagnostic algorithm on the basis of values for each glycan or glycopeptide obtained from a population of individuals having a disease or condition (e.g., ovarian cancer). In some examples, the methods include variable selection in a statistical model on the basis of values for each glycan or glycopeptide obtained from a population of individuals having ovarian cancer. Training a diagnostic algorithm may for example include determining a weighting vector in feature space for each category, or determining a function or function parameters.


In one embodiment, the reference value is the amount of a glycan or glycopeptide in a sample or samples derived from one individual. Alternatively, the reference value may be derived by pooling data obtained from multiple individuals, and calculating an average (for example, mean or median) amount for a glycan or glycopeptide. Thus, the reference value may reflect the average amount of a glycan or glycopeptide in multiple individuals. Said amounts may be expressed in absolute or relative terms, in the same manner as described herein.


In some examples, the reference value may be derived from the same sample as the sample that is being tested, thus allowing for an appropriate comparison between the two. For example, if the sample is derived from urine, the reference value is also derived from urine. In some examples, if the sample is a blood sample (e.g. a plasma or a serum sample), then the reference value will also be a blood sample (e.g. a plasma sample or a serum sample, as appropriate). When comparing between the sample and the reference value, the way in which the amounts are expressed is matched between the sample and the reference value. Thus, an absolute amount can be compared with an absolute amount, and a relative amount can be compared with a relative amount. Similarly, the way in which the amounts are expressed for classification with the diagnostic algorithm is matched to the way in which the amounts are expressed for training the diagnostic algorithm.


When the amounts of the glycan or glycopeptide are determined, the method may comprise comparing the amount of each glycan or glycopeptide to its corresponding reference value. When the cumulative amount of one, some or all the glycan or glycopeptides are determined, the method may comprise comparing the cumulative amount to a corresponding reference value. When the amounts of the glycan or glycopeptides are combined with each other in a formula to form an index value, the index value can be compared to a corresponding reference index value derived in the same manner.


The reference values may be obtained either within (i.e., constituting a step of) or external to the (i.e., not constituting a step of) methods described herein. In some examples, the methods include a step of establishing a reference value for the quantity of the markers. In other examples, the reference values are obtained externally to the method described herein and accessed during the comparison step of the invention.


In some examples, including any of the foregoing, training of a diagnostic algorithm may be obtained either within (i.e., constituting a step of) or external to (i.e., not constituting a step of) the methods set forth herein. In some examples, the methods include a step of training of a diagnostic algorithm. In some examples, the diagnostic algorithm is trained externally to the method herein and accessed during the classification step of the invention. The reference value may be determined by quantifying the amount of a glycan or glycopeptide in a sample obtained from a population of healthy individual(s). The diagnostic algorithm may be trained by quantifying the amount of a glycan or glycopeptide in a sample obtained from a population of healthy individual(s). As used herein, the term “healthy individual” refers to an individual or group of individuals who are in a healthy state, e.g., patients who have not shown any symptoms of the disease, have not been diagnosed with the disease and/or are not likely to develop the disease. Preferably said healthy individual(s) is not on medication affecting the disease and has not been diagnosed with any other disease. The one or more healthy individuals may have a similar sex, age and body mass index (BMI) as compared with the test individual. The reference value may be determined by quantifying the amount of a glycan or glycopeptide in a sample obtained from a population of individual(s) suffering from the disease. The diagnostic algorithm may be trained by quantifying the amount of a marker in a sample obtained from a population of individual(s) suffering from the disease. More preferably such individual(s) may have similar sex, age and body mass index (BMI) as compared with the test individual. The reference value may be obtained from a population of individuals suffering from ovarian cancer. The diagnostic algorithm may be trained by quantifying the amount of a glycan or glycopeptide in a sample obtained from a population of individuals suffering from ovarian cancer. Once the characteristic glycan or glycopeptide profile of ovarian cancer is determined, the profile of markers from a biological sample obtained from an individual may be compared to this reference profile to determine whether the test subject also has ovarian cancer. Once the diagnostic algorithm is trained to classify ovarian cancer, the profile of markers from a biological sample obtained from an individual may be classified by the diagnostic algorithm to determine whether the test subject is also at that particular stage of ovarian cancer.


VI. KITS

In some examples, including any of the foregoing, set forth herein is a kit comprising a glycopeptide standard, a buffer, and one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, set forth herein is a kit comprising a glycopeptide standard, a buffer, and one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, set forth herein is a kit for diagnosing or monitoring cancer in an individual wherein the glycan or glycopeptide profile of a sample from said individual is determined and the measured profile is compared with a profile of a normal patient or a profile of a patient with a family history of cancer. In some examples, the kit comprises one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262. In some examples, the kit comprises one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, set forth herein is a kit comprising a glycopeptide standard, a buffer, and one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, including any of the foregoing, set forth herein is a kit comprising a glycopeptide standard, a buffer, and one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, including any of the foregoing, set forth herein is a kit for diagnosing or monitoring cancer in an individual wherein the glycan or glycopeptide profile of a sample from said individual is determined and the measured profile is compared with a profile of a normal patient or a profile of a patient with a family history of cancer. In some examples, the kit comprises one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194. In some examples, the kit comprises one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, including any of the foregoing, set forth herein is a kit comprising the reagents for quantification of the oxidised, nitrated, and/or glycated free adducts derived from glycopeptides.


VII. CLINICAL ASSAYS

In some examples, including any of the foregoing, the biomarkers, methods, and/or kits may be used in a clinical setting for diagnosing patients. In some of these examples, the analysis of samples includes the use of internal standards. These standards may include one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262. These standards may include one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In a clinical setting, samples may be prepared (e.g., by digestion) to include one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In a clinical setting, samples may be prepared (e.g., by digestion) to include one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 to the concentration of another biomarker.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 to the concentration of another biomarker.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 to the amount of one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 to the amount of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, the kit may include software for computing the normalization of a glycopeptide MRM transition signal.


In some examples, including any of the foregoing, the kit may include software for quantifying the amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, the kit may include software for quantifying the relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.


In some examples, including any of the foregoing, a trained model is stored on a server which is accessed by a clinician performing a method, set forth herein. In some examples, the clinician inputs the quantification of the MRM transition signals from a patient's sample into a trained model which are stored on a server. In some examples, the server is accessed by the internet, wireless communication, or other digital or telecommunication methods.


In some examples, including any of the foregoing, a trained model is stored on a server which is accessed by a clinician performing a method, set forth herein. In some examples, the clinician inputs the quantification of the glycopeptide or glycopeptides consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 from a patient's sample into a trained model which are stored on a server. In some examples, the server is accessed by the internet, wireless communication, or other digital or telecommunication methods.


In some examples, including any of the foregoing, MRM transition signals 1-150 are stored on a server which is accessed by a clinician performing a method, set forth herein. In some examples, the clinician compares the MRM transition signals from a patient's sample to the MRM transition signals 1-150 which are stored on a server. In some examples, the server is accessed by the internet, wireless communication, or other digital or telecommunication methods.


In some examples, including any of the foregoing, a machine learning algorithm, which has been trained using the MRM transition signals 1-150, described herein, is stored on a server which is accessed by a clinician performing a method, set forth herein. In some examples, the machine learning algorithm, accessed remotely on a server, analyzes the MRM transition signals from a patient's sample. In some examples, the server is accessed by the internet, wireless communication, or other digital or telecommunication methods.


In some examples, including any of the foregoing, the biomarkers, methods, and/or kits may be used in a clinical setting for diagnosing patients. In some of these examples, the analysis of samples includes the use of internal standards. These standards may include one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194. These standards may include one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In a clinical setting, samples may be prepared (e.g., by digestion) to include one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In a clinical setting, samples may be prepared (e.g., by digestion) to include one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 to the concentration of another biomarker.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 to the concentration of another biomarker.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 to the amount of one or more glycopeptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, the amount of a glycan or glycopeptide may be assessed by comparing the amount of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 to the amount of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, including any of the foregoing, the kit may include software for computing the normalization of a glycopeptide MRM transition signal.


In some examples, including any of the foregoing, the kit may include software for quantifying the amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, including any of the foregoing, the kit may include software for quantifying the relative amount of a glycopeptide consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.


In some examples, including any of the foregoing, a trained model is stored on a server which is accessed by a clinician performing a method, set forth herein. In some examples, the clinician inputs the quantification of the MRM transition signals from a patient's sample into a trained model which are stored on a server. In some examples, the server is accessed by the internet, wireless communication, or other digital or telecommunication methods.


In some examples, including any of the foregoing, a trained model is stored on a server which is accessed by a clinician performing a method, set forth herein. In some examples, the clinician inputs the quantification of the glycopeptide or glycopeptides consisting of, or consisting essentially of, an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194 from a patient's sample into a trained model which are stored on a server. In some examples, the server is accessed by the internet, wireless communication, or other digital or telecommunication methods.


VII. EXAMPLES

Chemicals and Reagents. Glycoprotein standards purified from human serum/plasma were purchased from Sigma-Aldrich (St. Louis, Mo.). Sequencing grade trypsin was purchased from Promega (Madison, Wis.). Dithiothreitol (DTT) and iodoacetamide (IAA) were purchased from Sigma-Aldrich (St. Louis, Mo.). Human serum was purchased from Sigma-Aldrich (St. Louis, Mo.).


Sample Preparation. Serum samples and glycoprotein standards were reduced, alkylated and then digested with trypsin in a water bath at 37° C. for 18 hours.


LC-MS/MS Analysis. For quantitative analysis, tryptic digested serum samples were injected into an high performance liquid chromatography (HPLC) system coupled to triple quadrupole (QqQ) mass spectrometer. The separation was conducted on a reverse phase column. Solvents A and B used in the binary gradient were composed of mixtures of water, acetonitrile and formic acid. Typical positive ionization source parameters were utilized after source tuning with vendor supplied standards. The following ranges were evaluated: source spray voltage between 3-5 kV, temperature 250-350° C., and nitrogen sheath gas flow rate 20-40 psi. The scan mode of instrument used was dMRM.


For the glycoproteomic analysis, enriched serum glycopeptides were analyzed with a Q Exactive™ Hybrid Quadrupole-Orbitrap™ Mass spectrometer or an Agilent 6495B Triple Quadrupole LC/MS.


MRM Mass Spectroscopy settings, sample preparation, and reagents are set forth in Li, et al., Site-Specific Glycosylation Quantification of 50 serum Glycoproteins Enhanced by Predictive Glycopeptidomics for Improved Disease Biomarker Discovery, Anal. Chem. 2019, 91, 5433-5445; DOI: 10.1021/acs.analchem.9b00776, the entire contents of which are herein incorporated by reference in its entirety for all purposes.


Example 1—Identifying Glycopeptide Biomarkers

This Example refers to FIGS. 15 and 17-19.


As shown in FIG. 15, in step 1, samples from patients having ovarian cancer and samples from patients not having ovarian cancer were provided. In step 2, the samples were digested using protease enzymes to form glycopeptide fragments. In step 3, the glycopeptide fragments were introduced into a tandem LC-MS/MS instrument to analyze the retention time and MRM-MS transition signals associated with the aforementioned samples. In step 4, glycopeptides and glycan biomarkers were identified. Machine learning algorithms selected MRM-MS transition signals from a series of MS spectra and associated those signals with the calculated mass of certain glycopeptide fragments. See FIGS. 17-18 for MRM-MS transition signals identified by machine learning algorithms.


In step 5, the glycopeptides identified in samples from patients having ovarian cancer were compared using machine learning algorithms, including lasso regression, with the glycopeptides identified in samples from patients not having ovarian cancer. This comparison included a comparison of the types, absolute amounts, and relative amounts of glycopeptides. From this comparison, normalization of peptides, and relative abundance of glycopeptides was calculated. See FIG. 19 for output results of this comparison.


Example 2—Identifying Glycopeptide Biomarkers

This Example refers to FIG. 16.


As shown in FIG. 1, in step 1, samples from patients are provided. In step 2, the samples were digested using protease enzymes to form glycopeptide fragments. In step 3, the glycopeptide fragments were introduced into a tandem LC-MS/MS instrument to analyze the retention time and MRM-MS transition signals associated with the sample. In step 4, the glycopeptides were identified using machine learning algorithms which select MRM-MS transition signals and associate those signals with the calculated mass of certain glycopeptide fragments. In step 5, the data is normalized. In step 6, machine learning is used to analyzed the normalized data to identify biomarkers indicative of a patient having ovarian cancer.


IX. TABLES









TABLE 1







Transition Numbers for Glycopeptides from Glycopeptide Groups.









Transition No.
Compound Group
Compound Name












1
GP001-P01009|Alpha-1-antitrypsin|A1AT
A1AT-GP001_107_6501/6520


2
GP001-P01009|Alpha-1-antitrypsin|A1AT
A1AT-GP001_107_6513


3
GP001-P01009|Alpha-1-antitrypsin|A1AT
A1AT-GP001_271_5401


4
GP001-P01009|Alpha-1-antitrypsin|A1AT
A1AT-GP001_271_5402


5
GP001-P01009|Alpha-1-antitrypsin|A1AT
A1AT-GP001_271MC_5402


6
GP001-P01009|Alpha-1-antitrypsin|A1AT
A1AT-GP001_70_5402


7
GP001-P01009|Alpha-1-antitrypsin|A1AT
A1AT-GP001_70_5412


8
GP002-P04217|Alpha-1B-glycoprotein|A1BG
A1BG-GP002_179_5421/5402


9
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_1424_5402


10
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_1424_5402_z3


11
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_1424_5402_z5


12
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_247_5200


13
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_247_5402


14
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_55_5402


15
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_869_5401


16
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_869_5402


17
GP004-P01023|Alpha-2-macroglobulin|A2MG
A2MG-GP004_869_6301


18
GP005-P01011|Alpha-1-
AACT-GP005_271_7602



antichymotrypsin|AACT


19
GP006-P43652|Afamin|AFAM
AFAM-GP006_33_5402


20
GP007&008-P02763&P19652|Alpha-1-acid
AGP12-GP007&008_72MC_6503



glycoprotein 1&2|AGP12


21
GP007&008-P02763&P19652|Alpha-1-acid
AGP12-GP007&008_72MC_7601



glycoprotein 1&2|AGP12


22
GP007&008-P02763&P19652|Alpha-1-acid
AGP12-GP007&008_72MC_7602



glycoprotein 1&2|AGP12


23
GP007&008-P02763&P19652|Alpha-1-acid
AGP12-GP007&008_72MC_7603



glycoprotein 1&2|AGP12


24
GP007&008-P02763&P19652|Alpha-1-acid
AGP12-GP007&008_72MC_7613



glycoprotein 1&2|AGP12


25
GP007&008-P02763&P19652|Alpha-1-acid
AGP12-GP007&008_72MC_7614



glycoprotein 1&2|AGP12


26
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_103_6513



1|AGP1


27
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_103_7602



1|AGP1


28
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_103_7614



1|AGP1


29
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_103_7624



1|AGP1


30
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_103_8704



1|AGP1


31
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_103_9804



1|AGP1


32
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_33_5402



1|AGP1


33
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_33_6501



1|AGP1


34
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_33_6502



1|AGP1


35
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_93_6500



1|AGP1


36
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_93_6513



1|AGP1


37
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_93_7602/7621



1|AGP1


38
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_93_7603/7622



1|AGP1


39
GP007-P02763|Alpha-1-acid glycoprotein
AGP1-GP007_93_7611



1|AGP1


40
GP007-P02763|Alpha-1-acid gl7coprotein
AGP1-GP007_93_7613



1|AGP1


41
GP008-P19652|Alpha-1-acid glycoprotein
AGP2-GP008_103_6503



2|AGP2


42
GP013-P04114|Apolipoprotein B-
APOB-GP013_3411_5401



100|APOB


43
GP012-P02656|Apolipoprotein C-
APOC3-GP012_74_0310



III|APOC3


44
GP012-P02656|Apolipoprotein C-
APOC3-GP012_74_1102



III|APOC3


45
GP012-P02656|Apolipoprotein C-
APOC3-GP012_74_1111



III|APOC3


46
GP012-P02656|Apolipoprotein C-
APOC3-GP012_74_2110



III|APOC3


47
GP012-P02656|Apolipoprotein C-
APOC3-GP012_74Aoff_1102



III|APOC3


48
GP012-P02656|Apolipoprotein C-
APOC3-GP012_74MC_1101



III|APOC3


49
GP014-P05090|Apolipoprotein D|APOD
APOD-GP014_98_5402/5421


50
GP014-P05090|Apolipoprotein D|APOD
APOD-GP014_98_5410


51
GP014-P05090|Apolipoprotein D|APOD
APOD-GP014_98_6510


52
GP014-P05090|Apolipoprotein D|APOD
APOD-GP014_98_6530


53
GP014-P05090|Apolipoprotein D|APOD
APOD-GP014_98_9800


54
GP015-P02749|Beta-2-glycoprotein1|APOH
APOH-GP015_253_5401


55
GP022-P20807|Calpain-3|CAN3
CAN3-GP022_366_6513


56
GP023-P00450|Ceruloplasmin|CERU
CERU-GP023_138_6503/6522


57
GP024-
CFAH-GP024_1029_5431



P08603|ComplementFactorH|CFAH


58
GP024-
CFAH-GP024_1029_7500



P08603|ComplementFactorH|CFAH


59
GP024-
CFAH-GP024_882_5420/5401



P08603|ComplementFactorH|CFAH


60
GP024-
CFAH-GP024_911_5402/5421



P08603|ComplementFactorH|CFAH


61
GP025-
CFAI-GP025_70_5401



P05156|ComplementFactorI|CFAI


62
GP025-
CFAI-GP025_70_5402



P05156|ComplementFactorI|CFAI


63
GP026-P10909|Clusterin|CLUS
CLUS-GP026_291_6503


64
GP026-P10909|Clusterin|CLUS
CLUS-GP026_86_6503


65
GP028-P01024|ComplementC3|CO3
CO3-GP028_85_5200


66
GP029&030-
CO4A&CO4B-



P0C0L4&P0C0L5|ComplementC4-
GP029&030_1328_5402



A&B|CO4A&CO4B


67
GP033-
CO8A-GP033_437_5200



P07357|ComplementComponentC8AChain|CO8A


68
GP034-
CO8B-GP034_553_5410



P07358|ComplementComponentC8BChain|CO8B


69
GP036-P02765|Alpha-2-HS-
FETUA-GP036_156_5400



glycoprotein|FETUA


70
GP036-P02765|Alpha-2-HS-
FETUA-GP036_176_5401



glycoprotein|FETUA


71
GP036-P02765|Alpha-2-HS-
FETUA-GP036_346_2200



glycoprotein|FETUA


72
GP042-P02790|Hemopexin|HEMO
HEMO-GP042_187_5412/5431


73
GP044-P00738|Haptoglobin|HPT
HPT-GP044_207_11904


74
GP044-P00738|Haptoglobin|HPT
HPT-GP044_207_11915


75
GP044-P00738|Haptoglobin|HPT
HPT-GP044_207_121005


76
GP044-P00738|Haptoglobin|HPT
HPT-GP044_241_6503


77
GP044-P00738|Haptoglobin|HPT
HPT-GP044_241_6512


78
GP044-P00738|Haptoglobin|HPT
HPT-GP044_241_6513


79
GP044-P00738|Haptoglobin|HPT
HPT-GP044_241_7613


80
GP045-P04196|Histidine-rich
HRG-GP045_125_5421/5402



Glycoprotein|HRG


81
GP045-P04196|Histidine-rich
HRG-GP045_345_5412



Glycoprotein|HRG


82
GP046&047-
IgA12-GP046&047_144_5502



P01876&P01877|Immunoglobulin heavy constant



alpha 1&2|IgA12


83
GP047-P01877|Immunoglobulin heavy constant
IgA2-GP047_205_5411



alpha 2|IgA2


84
GP047-P01877|Immunoglobulin heavy constant
IgA2-GP047_205_5412



alpha 2|IgA2


85
GP047-P01877|Immunoglobulin heavy constant
IgA2-GP047_205_5510



alpha 2|IgA2


86
GP049-P01859|Immunoglobulin heavy constant
IgG2-GP049_297_3410



gamma 2|IgG2


87
GP049-P01859|Immunoglobulin heavy constant
IgG2-GP049_297_4411



gamma 2|IgG2


88
GP053-P01871|Immunoglobulin heavy constant
IgM-GP053_439_6200



mu|IgM


89
GP053-P01871|Immunoglobulin heavy constant
IgM-GP053_46_5601



mu|IgM


90
GP054-P19827|Inter-alpha-trypsin inhibitor
ITIH1-GP054_285_5511



heavy chain H1|ITIH1


91
GP055-Q14624|Inter-alpha-trypsin inhibitor
ITIH4-GP055_517_5420/5401



heavy chain H4|ITIH4


92
GP056-P03952|Plasma Kallikrein|KLKB1
KLKB1-GP056_494_5400


93
GP056-P03952|Plasma Kallikrein|KLKB1
KLKB1-GP056_494_5402


94
GP056-P03952|Plasma Kallikrein|KLKB1
KLKB1-GP056_494_6503


95
GP003-P02750|Leucine-richAlpha-2-
pep-A2GL-GP003_GQTLLAVAK



glycoprotein|A2GL


96
GP007-P02763|Alpha-1-acid glycoprotein
pep-AGP1-



1|AGP1
GP007_YVGGQEHFAHLLILR


97
GP011-P02647|Apolipoprotein A-I|APOA1
pep-APOA1-GP011_LAEYHAK


98
-P02654|Apolipoprotein C-I|APOC1
pep-APOC1-QSELSAK


99
GP032-
pep-CO6-GP032_GFVVAGPSR



P13671|ComplementcomponentC6|CO6


100
GP044-P00738|Haptoglobin|HPT
pep-HPT-




GP044_LPECEAVCGKPK


101
-P01344|Insulin-like growth factor-
pep-IGF2-GIVEECCFR



II|IGF2


102
-P027531|Retinol binding protein
pep-RET4-



4|RET4
LLNLDGTCADSYSFVFSR


103
GP064-P02787|Serotransferrin|TRFE
pep-TRFE-GP064_DSAHGFLK


104
GP060-P27169|Serum
PON1-GP060_253_4301



paraoxonase/arylesterase 1|PON1


105
GP060-P27169|Serum
PON1-GP060_324_5420



paraoxonase/arylesterase 1|PON1


106
GP060-P27169|Serum
PON1-GP060_324_6501



paraoxonase/arylesterase 1|PON1


107
GP060-P27169|Serum
PON1-GP060_324_6502



paraoxonase/arylesterase 1|PON1


108
GP001-P01009|Alpha-1-antitrypsin|A1AT
QuantPep-A1AT-




GP001_AVLTIDEK


109
GP003-P02750|Leucine-richAlpha-2-
QuantPep-A2GL-



glycoprotein|A2GL
GP003_DLLLPQPDLR


110
GP005-P01011|Alpha-1-
QuantPep-AACT-



antichymotrypsin|AACT
GP005_ADLSGITGAR


111
GP006-P43652|Afamin|AFAM
QuantPep-AFAM-




GP006_SDVGFLPPFPTLDPEEK


112
GP007&008-P02763&P19652|Alpha-1-
QuantPep-AGP12-



acid glycoprotein 1&2|AGP12
GP007&008_WFYIASAFR


113
GP007-P02763|Alpha-1-acid
QuantPep-AGP1-



glycoprotein 1|AGP1
GP007_EQLGEFYEALDCLR


114
GP011-P02647|Apolipoprotein A-I|APOA1
QuantPep-APOA1-




GP011_DLATVYVDVLK


115
GP014-P05090|Apolipoprotein D|APOD
QuantPep-APOD-




GP014_VLNQELR


116
GP016-095445|Apolipoprotein M|APOM
QuantPep-APOM-




GP016_AFLLTPR


117
GP018-O75882|Attractin|ATRN
QuantPep-ATRN-




GP018_SEAACLAAGPGIR


118
GP026-P10909|Clusterin|CLUS
QuantPep-CLUS-




GP026_ASSIIDELFQDR


119
GP033-
QuantPep-CO8A-



P07357|ComplementComponentC8AChain|CO8A
GP033_LYYGDDEK


120
GP035-P00748|Coagulation factor
QuantPep-FA12-



XII|FA12
GP035_VVGGLVALR


121
GP036-P02765|Alpha-2-HS-
QuantPep-FETUA-



glycoprotein|FETUA
GP036_AHYDLR


122
GP044-P00738|Haptoglobin|HPT
QuantPep-HPT-




GP044_ILGGHLDAK


123
GP049-P01859|Immunoglobulin
QuantPep-IgG2-



heavy constant gamma 2|IgG2
GP049_GLPAPIEK


124
GP054-P19827|Inter-alpha-trypsin inhibitor
QuantPep-ITIH1-



heavy chain H1|ITIH1
GP054_LDAQASFLPK


125
GP056-P03952|Plasma Kallikrein|KLKB1
QuantPep-KLKB1-




GP056_TGAVSGHSLK


126
GP057-P01042|Kininogen-1|KNG1
QuantPep-KNG1-




GP057_YFIDFVAR


127
GP060-P27169|Serum
QuantPep-PON1-



paraoxonase/arylesterase 1|PON1
GP060_YVYIAELLAHK


128
GP061-P49908|Selenoprotein P|SEPP1
QuantPep-SEPP1-




GP061_VSLATVDK


129
GP064-P02787|Serotransferrin|TRFE
QuantPep-TRFE-




GP064_DDTVCLAK


130
GP065-P02766|Transthyretin|TTR
QuantPep-TTR-




GP065_TSESGELHGLTTEEEFVEGIYK


131
GP066-Q9UPW8|Protein unc-
QuantPep-UN13A-



13HomologA|UN13A
GP066_LDLGLTVEVWNK


132
GP063-P00734|Prothrombin|THRB
THRB-GP063_121_5420/5401


133
GP063-P00734|Prothrombin|THRB
THRB-GP063_121_5421/5402


134
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_432_5401


135
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_432_5402


136
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_432_5412


137
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_630_5400


138
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_630_6410


139
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_630_6411


140
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_630_6502


141
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_630_6503


142
GP064-P02787|Serotransferrin|TRFE
TRFE-GP064_630_6513


143
GP066-Q9UPW8|Protein unc-
UN13A-GP066_1005_3420



13HomologA|UN13A


144
GP066-Q9UPW8|Protein unc-
UN13A-GP066_1005_5431



13HomologA|UN13A


145
GP066-Q9UPW8|Protein unc-
UN13A-GP066_1005_7420



13HomologA|UN13A


146
GP067-P04004|Vitronectin|VTNC
VTNC-GP067_169_5401


147
GP067-P04004|Vitronectin|VTNC
VTNC-GP067_242_6502


148
GP067-P04004|Vitronectin|VTNC
VTNC-GP067_242_6503


149
GP067-P04004|Vitronectin|VTNC
VTNC-GP067_86_6503


150
GP068-P25311|Zinc-alpha-2-
ZA2G-GP068_112_5412



glycoprotein|ZA2G
















TABLE 2







Transition Numbers with Precursor Ion and Product Ion (m/z)









Transition No.
Precursor Ion
Product Ion












1
1195.4
366.1


2
1341
366.1


3
1223.9
366.1


4
991.2
366.1


5
1149.9
366.1


6
1078.5
274.1


7
1107.7
366.1


8
1209.5
366.1


9
1093.1
366.1


10
1456.7
1183.6


11
874.4
1183.6


12
1239.2
1314.2


13
1189.2
366.1


14
1151.6
366.1


15
1066.7
366.1


16
1124.9
366.1


17
1322.3
366.1


18
1172.7
366.1


19
1134.1
366.1


20
1152.5
366.1


21
1109.1
366.1


22
1167.3
366.1


23
1225.5
366.1


24
1254.7
366.1


25
1313.1
366.1


26
1262
366.1


27
1238
366.1


28
1110.8
366.1


29
1147.3
366.1


30
1165.6
366.1


31
1256.8
366.1


32
1196.5
366.1


33
1215
366.1


34
1287.7
366.1


35
1301.9
366.1


36
1231.8
274.1


37
1213.8
366.1


38
1286.6
366.1


39
1177.2
366.1


40
1323.1
366.1


41
1208.6
366.1


42
1174.2
366.1


43
975.4
204.1


44
1028.8
274.1


45
980.4
274.1


46
937.4
366.1


47
1005.1
274.1


48
989.1
274.1


49
1115.7
366.1


50
1341.6
366.1


51
1098
366.1


52
1171
366.1


53
1335.3
366.1


54
1055.8
366.1


55
1236.2
366.1


56
1189.5
366.1


57
1259.5
366.1


58
908.6
366.1


59
984.7
366.1


60
1256.1
366.1


61
993.1
366.1


62
1090.1
366.1


63
952.1
366.1


64
1270.2
366.1


65
1157.9
204.1


66
1103.8
366.1


67
850.7
366.1


68
1152.4
366.1


69
1132.2
366.1


70
1070.4
366.1


71
916.1
366.1


72
1252.5
366.1


73
1247.7
366.1


74
1335.1
366.1


75
1378.9
366.1


76
1165
366.1


77
1128.8
366.1


78
1201.5
366.1


79
1292.8
366.1


80
1407.9
366.1


81
994.4
366.1


82
1075.1
366.1


83
1006.8
366.1


84
1103.8
366.1


85
977.5
366.1


86
868.1
204.1


87
1019.1
204.1


88
1248.5
204.1


89
901.9
366.1


90
1039.1
366.1


91
1181.5
366.1


92
968.2
366.1


93
1114.7
366.1


94
1277.8
366.1


95
450.8
501.3


96
877
745.9


97
416.2
647.3


98
381.7
305.2


99
445.2
487.3


100
694.3
244.2


101
585.3
771.3


102
1033
742.4


103
437.7
464.3


104
910.4
366.1


105
1057.7
366.1


106
1149.3
366.1


107
1221.5
366.1


108
444.8
605.3


109
590.3
342.2


110
480.8
404.2


111
944.5
502.3


112
580.8
827.4


113
871.9
563.3


114
618.3
736.4


115
436.3
545.3


116
409.2
486.3


117
636.8
499.3


118
697.4
922.4


119
501.7
726.3


120
442.3
685.4


121
387.7
209.1


122
462.3
697.4


123
412.7
486.3


124
545.3
662.4


125
478.8
230.1


126
515.8
720.4


127
660.4
529.3


128
416.7
646.4


129
461.2
491.3


130
819.1
609.3


131
693.9
675.4


132
904.4
366.1


133
1001.4
366.1


134
1131.1
366.1


135
921.4
366.1


136
957.9
366.1


137
1035.6
366.1


138
1112.2
366.1


139
1185
366.1


140
1018.1
366.1


141
1076.4
366.1


142
1105.6
366.1


143
1382.6
366.1


144
1227.5
366.1


145
1199.2
366.1


146
942.4
366.1


147
1336.3
366.1


148
1409.1
366.1


149
1239
366.1


150
1472.6
366.1





MS1 and MS2 resolution was 1 unit.













TABLE 3







Transition Numbers with Retention Time, ΔRetention


Time, Fragmentor and Collision Energy











Transition
Ret Time
Delta Ret

Collision


No.
(min)
Time
Fragmentor
Energy














1
43.1
3
380
30


2
43.4
3
380
34


3
29.4
3
380
30


4
29.8
3
380
24


5
42.5
4
380
28


6
46
4
380
26


7
46
4
380
27


8
24
2
380
36


9
43.7
3
380
22


10
43.7
3
380
22


11
43.7
3
380
20


12
32
2
380
25


13
35.2
3
380
26


14
41.1
3
380
23


15
26
2
380
22


16
27
2
380
25


17
26.2
2
380
24


18
19
1.2
380
35


19
9.3
1
380
30


20
38.2
3
380
28


21
37.3
3
380
30


22
36.5
3
380
29


23
38
3
380
31


24
37.8
3
380
31


25
39.4
3
380
27


26
3.7
1.2
380
32


27
3.4
1
380
31


28
3.8
1.2
380
27


29
3.8
1.2
380
28


30
3.7
1.2
380
29


31
3.5
1
380
31


32
29
2
380
30


33
27.9
2
380
30


34
28.6
2
380
32


35
17
1
380
30


36
17.4
1.2
380
31


37
16.9
1.2
380
30


38
17.3
1.2
380
32


39
16.8
1.2
380
30


40
17.2
1.2
380
33


41
3
1.2
380
30


42
10.9
1.2
380
30


43
28.3
1.6
380
24


44
30.2
2
380
25


45
29.9
1.6
380
24


46
29.1
1.6
380
22


47
30
2
380
24


48
28.2
2
380
24


49
21.6
1.2
380
34


50
21.6
1.2
380
35


51
21.5
1.2
380
34


52
22.2
1.2
380
35


53
21.6
1.2
380
39


54
14.4
2
380
33


55
24.3
2
380
37


56
13.5
2
380
36


57
9.6
1.2
380
38


58
10.2
1.2
380
29


59
11.8
1.2
380
31


60
10.5
1.2
380
38


61
4
1.2
380
30


62
4.4
1.2
380
34


63
3.7
1.2
380
30


64
6.4
1.2
380
38


65
19.5
1.2
380
30


66
13.6
1.2
380
34


67
11.2
1.2
380
28


68
18
2
380
35


69
19.3
1.2
380
30


70
20.6
1.2
380
26


71
16.3
1.2
380
22


72
16.2
1.2
380
37


73
10.7
1.2
380
31


74
10.8
1.4
380
34


75
10.7
1.2
380
35


76
22.2
1.3
380
29


77
21.4
1.2
380
28


78
22.1
1.2
380
30


79
22
1.4
380
32


80
20.6
1.2
380
41


81
3.6
2
380
25


82
40.1
2
380
26


83
10.7
1.2
380
24


84
11.3
1.2
380
27


85
10.2
1.2
380
24


86
10.6
1
380
21


87
11.3
1
380
25


88
22.2
1.2
380
30


89
4.4
1
380
21


90
30
2
380
32


91
23.7
2
380
36


92
20
1.2
380
30


93
19.5
1.2
380
34


94
20.6
1.2
380
38


95
13.45
1
380
11


96
20
1
380
33


97
3.85
1
380
10


98
3.55
1
380
9


99
12.1
1
380
11


100
8.3
1
380
25


101
13.5
1
380
16


102
29.9
1
380
32


103
8.7
1
380
14


104
17
1.2
380
29


105
25.3
2
380
33


106
25.2
2
380
35


107
24.9
2
380
37


108
12
1
380
11


109
22.1
1.2
380
15


110
11.7
1
380
13


111
33.5
1.2
380
29


112
27.9
1
380
16


113
29.4
1
380
27


114
26.2
1
380
17


115
8.8
1
380
11


116
17.4
1
380
10


117
13.1
1
380
18


118
29.5
1
380
20


119
8.1
1
380
13


120
16.8
1
380
11


121
5.6
1
380
12


122
8.9
1
380
12


123
12
1
380
12


124
17.1
1.2
380
15


125
4.1
1
380
16


126
23
1
380
14


127
23.3
1
380
19


128
10.3
1
380
10


129
8.7
1
380
12


130
24.2
1
380
25


131
32
1
380
20


132
3.1
1.2
380
29


133
3.1
1.2
380
31


134
18.9
1.2
380
28


135
19.7
1.2
380
22


136
19.7
1.2
380
23


137
21.7
1.2
380
25


138
21.7
1.2
380
25


139
22.2
1.4
380
25


140
23.8
1.6
380
25


141
24.1
1.2
380
26


142
24.1
1.2
380
27


143
24.2
2
380
41


144
24.3
2
380
37


145
25.9
2
380
36


146
17.6
1.2
380
30


147
29.7
3
380
40


148
29.3
3
380
41


149
14.6
2
380
37


150
19.6
1.2
380
43





Cell accelerator voltage was 5.













TABLE 4







Glycan Residue Compound Numbers, Molecular


Mass, and Glycan Fragment mass-to-charge


(m/z) (+2) & (m/z) (+3) ratios












Composition
mass
m/z (+2)
m/z (+3)
















3200
910.327
456.1708
304.449633



3210
1056.386
529.2003
353.135967



3300
1113.407
557.7108
372.142967



3310
1259.465
630.7398
420.828967



3320
1405.523
703.7688
469.514967



3400
1316.487
659.2508
439.8363



3410
1462.544
732.2793
488.521967



3420
1608.602
805.3083
537.207967



3500
1519.566
760.7903
507.5293



3510
1665.624
833.8193
556.2153



3520
1811.682
906.8483
604.9013



3600
1722.645
862.3298
575.2223



3610
1868.703
935.3588
623.9083



3620
2014.761
1008.3878
672.5943



3630
2160.89
1081.4523
721.303967



3700
1925.724642
963.869621
642.915514



3710
2071.782551
1036.898576
691.601484



3720
2217.84046
1109.92753
740.287453



3730
2363.898369
1182.956485
788.973423



3740
2509.956277
1255.985439
837.659392



4200
1072.380603
537.1976015
358.467501



4210
1218.438512
610.226556
407.153471



4300
1275.459976
638.737288
426.160625



4301
1566.555392
784.284996
523.192431



4310
1421.517884
711.766242
474.846595



4311
1712.613301
857.3139505
571.8784



4320
1567.575793
784.7951965
523.532564



4400
1478.539348
740.276974
493.853749



4401
1769.634765
885.8246825
590.885555



4410
1624.597257
813.3059285
542.539719



4411
1915.692673
958.8536365
639.571524



4420
1770.655166
886.334883
591.225689



4421
2061.750582
1031.882591
688.257494



4430
1916.713074
959.363837
639.911658



4431
2207.808491
1104.911546
736.943464



4500
1681.618721
841.8166605
561.546874



4501

1.0073
1.0073



4510
1972.714137
987.3643685
658.578679



4511
2118.772046
1060.393323
707.264649



4520
1973.734538
987.874569
658.918813



4521
2264.829955
1133.422278
755.950618



4530
2119.792447
1060.903524
707.604782



4531
2410.887864
1206.451232
804.636588



4540
2265.850356
1133.932478
756.290752



4541
2556.945772
1279.480186
853.322557



4600
1884.698093
943.3563465
629.239998



4601
2175.79351
1088.904055
726.271803



4610
2030.756002
1016.385301
677.925967



4611
2321.851418
1161.933009
774.957773



4620
2176.813911
1089.414256
726.611937



4621
2467.909327
1234.961964
823.643742



4630
2322.87182
1162.44321
775.297907



4631
2613.967236
1307.990918
872.329712



4641
2760.025145
1381.019873
921.015682



4650
2614.987637
1308.501119
872.669846



4700
2087.777466
1044.896033
696.933122



4701
2378.872882
1190.443741
793.964927



4710
2233.835374
1117.924987
745.619091



4711
2524.930791
1263.472696
842.650897



4720
2379.893283
1190.953942
794.305061



4730
2525.951192
1263.982896
842.991031



5200
1234.433426
618.224013
412.485109



5210
1380.491335
691.2529675
461.171078



5300
1437.512799
719.7636995
480.178233



5301
1728.608215
865.3114075
577.210038



5310
1583.570708
792.792654
528.864203



5311
1874.666124
938.340362
625.896008



5320
1729.628617
865.8216085
577.550172



5400
1640.592171
821.3033855
547.871357



5401
1931.687588
966.851094
644.903163



5402
2222.783005
1112.398803
741.934968



5410
1786.65008
894.33234
596.557327



5411
2077.745497
1039.880049
693.589132



5412
2368.840913
1185.427757
790.620938



5420
1932.707989
967.3612945
645.243296



5421
2223.803406
1112.909003
742.275102



5430
2078.765898
1040.390249
693.929266



5431
2369.861314
1185.937957
790.961071



5432
2660.956731
1331.485666
887.992877



5500
1843.671544
922.843072
615.564481



5501
2134.766961
1068.390781
712.596287



5502
2425.862377
1213.938489
809.628092



5510
1989.729453
995.8720265
664.250451



5511
2280.824869
1141.419735
761.282256



5512
2571.920286
1286.967443
858.314062



5520
2135.787362
1068.900981
712.936421



5521
2426.882778
1214.448689
809.968226



5522
2717.978195
1359.996398
907.000032



5530
2281.84527
1141.929935
761.62239



5531
2572.940687
1287.477644
858.654196



5541
2718.998596
1360.506598
907.340165



5600
2046.750917
1024.382759
683.257606



5601
2337.846333
1169.930467
780.289411



5602
2628.94175
1315.478175
877.321217



5610
2192.808825
1097.411713
731.943575



5611
2483.904242
1242.959421
828.975381



5612
2774.999658
1388.507129
926.007186



5620
2338.866734
1170.440667
780.629545



5621
2629.962151
1315.988376
877.66135



5631
2776.020059
1389.01733
926.34732



5650
2777.040461
1389.527531
926.687454



5700
2249.830289
1125.922445
750.95073



5701
2540.925706
1271.470153
847.982535



5702
2832.021122
1417.017861
945.014341



5710
2395.888198
1198.951399
799.636699



5711
2686.983614
1344.499107
896.668505



5712
2978.079031
1490.046816
993.70031



5720
2541.946107
1271.980354
848.322669



5721
2833.041523
1417.528062
945.354474



5730
2688.004016
1345.009308
897.008639



5731
2979.099432
1490.557016
994.040444



6200
1396.48625
699.250425
466.502717



6210
1542.544159
772.2793795
515.188686



6300
1599.565622
800.790111
534.195841



6301
1890.661039
946.3378195
631.227646



6310
1745.623531
873.8190655
582.88181



6311
2036.718948
1019.366774
679.913616



6320
1891.68144
946.84802
631.56778



6400
1802.644995
902.3297975
601.888965



6401
2093.740411
1047.877506
698.92077



6402
2384.835828
1193.425214
795.952576



6410
1948.702904
975.358752
650.574935



6411
2239.79832
1120.90646
747.60674



6412
2530.893737
1266.454169
844.638546



6420
2094.760813
1048.387707
699.260904



6421
2385.856229
1193.935415
796.29271



6432
2823.009554
1412.512077
942.010485



6500
2005.724367
1003.869484
669.582089



6501
2296.819784
1149.417192
766.613895



6502
2587.9152
1294.9649
863.6457



6503
2879.010617
1440.512609
960.677506



6510
2151.782276
1076.898438
718.268059



6511
2442.877693
1222.446147
815.299864



6512
2733.973109
1367.993855
912.33167



6513
3025.068526
1513.541563
1009.36348



6520
2297.840185
1149.927393
766.954028



6521
2588.935602
1295.475101
863.985834



6522
2880.031018
1441.022809
961.017639



6530
2443.898094
1222.956347
815.639998



6531
2734.99351
1368.504055
912.671803



6532
3026.088927
1514.051764
1009.70361



6540
2589.956003
1295.985302
864.325968



6541
2881.051419
1441.53301
961.357773



6600
2208.80374
1105.40917
737.275213



6601
2499.899157
1250.956879
834.307019



6602
2790.994573
1396.504587
931.338824



6603
3082.08999
1542.052295
1028.37063



6610
2354.861649
1178.438125
785.961183



6611
2645.957065
1323.985833
882.992988



6612
2937.052482
1469.533541
980.024794



6613
3228.147898
1615.081249
1077.0566



6620
2500.919558
1251.467079
834.647153



6621
2792.014974
1397.014787
931.678958



6622
3083.110391
1542.562496
1028.71076



6623
3374.205807
1688.110204
1125.74257



6630
2646.977466
1324.496033
883.333122



6631
2938.072883
1470.043742
980.364928



6632
3229.168299
1615.59145
1077.39673



6640
2793.035375
1397.524988
932.019092



6641
3084.130792
1543.072696
1029.0509



6642
3375.226208
1688.620404
1126.0827



6652
3521.284117
1761.649359
1174.76867



6700
2411.883113
1206.948857
804.968338



6701
2702.978529
1352.496565
902.000143



6703
3285.169362
1643.591981
1096.06375



6710
2557.941021
1279.977811
853.654307



6711
2849.036438
1425.525519
950.686113



6711
2849.036438
1425.525519
950.686113



6712
3140.131854
1571.073227
1047.71792



6713
3431.227271
1716.620936
1144.74972



6713
3431.227271
1716.620936
1144.74972



6720
2703.99893
1353.006765
902.340277



6721
2995.094347
1498.554474
999.372082



6721
2995.094347
1498.554474
999.372082



6730
2850.056839
1426.03572
951.026246



6731
3141.152255
1571.583428
1048.05805



6740
2996.114748
1499.064674
999.712216



7200
1558.539073
780.2768365
520.520324



7210
1704.596982
853.305791
569.206294



7400
1964.697818
983.356209
655.906573



7401
2255.793235
1128.903918
752.938378



7410
2110.755727
1056.385164
704.592542



7411
2401.851144
1201.932872
801.624348



7412
2692.94656
1347.48058
898.656153



7420
2256.813636
1129.414118
753.278512



7421
2547.909052
1274.961826
850.310317



7430
2402.871545
1202.443073
801.964482



7431
2693.966961
1347.990781
898.996287



7432
2985.062378
1493.538489
996.028093



7500
2167.777191
1084.895896
723.599697



7501
2458.872607
1230.443604
820.631502



7510
2313.8351
1157.92485
772.285667



7511
2604.930516
1303.472558
869.317472



7512
2896.025933
1449.020267
966.349278



7600
2370.856563
1186.435582
791.292821



7601
2661.95198
1331.98329
888.324627



7602
2953.047396
1477.530998
985.356432



7603
3244.142813
1623.078707
1082.38824



7604
3535.23823
1768.626415
1179.42004



7610
2516.914472
1259.464536
839.978791



7611
2808.009889
1405.012245
937.010596



7612
3099.105305
1550.559953
1034.0424



7613
3390.200722
1696.107661
1131.07421



7614
3681.296138
1841.655369
1228.10601



7620
2662.972381
1332.493491
888.66476



7621
2954.067798
1478.041199
985.696566



7622
3245.163214
1623.588907
1082.72837



7623
3536.258631
1769.136616
1179.76018



7632
3391.221123
1696.617862
1131.41434



7640
2955.088199
1478.5514
986.0367



7700
2573.935936
1287.975268
858.985945



7701
2865.031352
1433.522976
956.017751



7702
3156.126769
1579.070685
1053.04956



7703
3447.222186
1724.618393
1150.08136



7710
2719.993845
1361.004223
907.671915



7711
3011.089261
1506.551931
1004.70372



7712
3302.184678
1652.099639
1101.73553



7713
3593.280094
1797.647347
1198.76733



7714
3884.375511
1943.195056
1295.79914



7720
2866.051754
1434.033177
956.357885



7721
3157.14717
1579.580885
1053.38969



7722
3448.242587
1725.128594
1150.4215



7730
3012.109662
1507.062131
1005.04385



7731
3303.205079
1652.60984
1102.07566



7732
3594.300495
1798.157548
1199.10747



7740
3158.167571
1580.091086
1053.72982



7741
3449.262988
1725.638794
1150.76163



7751
3595.320897
1798.667749
1199.4476



8200
1720.591897
861.3032485
574.537932



9200
1882.64472
942.32966
628.55554



9210
2028.702629
1015.358615
677.24151



10200
2044.697544
1023.356072
682.573148



11200
2206.750367
1104.382484
736.590756



12200
2368.80319
1185.408895
790.608363

















TABLE 5







Glycan Residue Compound Numbers, Molecular


Mass, and Classification










Compound
Glycan Mass
Glycan Composition
Class













3200
910.328
GlcNAc2Man3
HM


3200


3210
1056.386
GlcNAc2Man3Fuc1
HM-F


3210


3300
1113.407
Hex3HexNAc3
C


3300


3310
1259.465
Hex3HexNAc3Fuc1
C-F


3310


3320
1405.523
Hex3HexNAc3Fuc2
C-F


3400
1316.487
Hex3HexNAc4
C


3410
1462.544
Hex3HexNAc4Fuc1
C-F


3410


3420
1608.602
Hex3HexNAc4Fuc2
C-F


3500
1519.566
Hex3HexNAc5
C


3510
1665.624
Hex3HexNAc5Fuc1
C-F


3520
1811.682
Hex3HexNAc5Fuc2
C-F


3600
1722.645
Hex3HexNAc6
C


3610
1868.703
Hex3HexNAc6Fuc1
C-F


3620
2014.761
Hex3HexNAc6Fuc2
C-F


3630
2160.819
Hex3HexNAc6Fuc3
C-F


3700
1925.725
Hex3HexNAc7
C


3710
2071.783
Hex3HexNAc7Fuc1
C-F


3720
2217.841
Hex3HexNAc7Fuc2
C-F


3720
2217.841
Hex3HexNAc7Fuc2
C-F


3730
2363.898
Hex3HexNAc7Fuc3
C-F


3740
2509.956
Hex3HexNAc7Fuc4
C-F


4200
1072.381
GlcNAc2Man4
HM


4200


4210
1218.438
GlcNAc2Man4Fuc1
HM-F


4210


4300
1275.460
Hex4HexNAc3
CH


4300


4301
1566.555
Hex4HexNAC3Neu5Ac1
C-S


4301
1566.555
Hex4HexNAC3Neu5Ac1
C-S


4301


4310
1421.518
Hex4HexNAc3Fuc1
C/H-F


4310
1566.555
Hex4HexNAC3Neu5Ac1
C-S


4310


4311
1712.613
Hex4HexNAc3Fuc1Neu5Ac1
C-FS


4311


4320


4400
1478.539
Hex4HexNAc4
CH


4400


4401
1769.635
Hex4HexNAc4Neu5Ac1
C-S


4410
1624.597
Hex4HexNAc4Fuc1
C/H-F


4410


4411
1915.693
Hex4HexNAc4Fuc1Neu5Ac1
C-FS


4411


4420
1770.655
Hex4HexNAc4Fuc2
C/H-F


4420


4421
2061.751
Hex4HexNAc4Fuc2Neu5Ac1
C-FS


4430
1916.713
Hex4HexNAc4Fuc3
C/H-F


4431
2207.808
Hex4HexNAc4Fuc3Neu5Ac1
C-FS


4431
2207.808
Hex4HexNAc4Fuc3Neu5Ac1
C-FS


4531
2410.888
Hex4HexNAc5Fuc3Neu5Ac1
C-FS


4541
2556.946
Hex4HexNAc5Fuc4Neu5Ac1
C-FS


4600
1884.698
Hex4HexNAc6
C


4601
2175.794
Hex4HexNAc6Neu5Ac1
C-S


4610
2030.756
Hex4HexNAc6Fuc1
C-F


4611
2321.851
Hex4HexNAc6Fuc1Neu5Ac1
C-FS


4620
2176.814
Hex4HexNAc6Fuc2
C-F


4621
2467.909
Hex4HexNAc6Fuc2Neu5Ac1
C-FS


4630
2322.872
Hex4HexNAc6Fuc3
C-F


4641
2760.025
Hex4HexNAc6Fuc4Neu5Ac1
C-FS


4650
2614.988
Hex4HexNAc6Fuc5
C-F


4700
2087.778
Hex4HexNAc7
C


4701
2378.873
Hex4HexNAc7Neu5Ac1
C-S


4710
2233.835
Hex4HexNAc7Fuc1
C-F


4711
2524.931
Hex4HexNAc7Fuc1Neu5Ac1
C-FS


4720
2379.893
Hex4HexNAc7Fuc2
C-F


4730
2525.951
Hex4HexNAc7Fuc3
C-F


5200


5200


5210
1380.491
GlcNAc2Man5Fuc1
HM-F


5300
1437.513
Hex5HexNAc3
H


5300


5301
1728.608
Hex5HexNAc3Neu5Ac1
H-S


5301


5310
1583.571
Hex5HexNAc3Fuc1
H-F


5310


5311
1874.666
Hex5HexNAc3Fuc1Neu5Ac1
H-FS


5311


5320
1729.629
Hex5HexNAc3Fuc2
H-F


5320


5400


5401


5401


5402


5410


5411

Hex5HexNAc4Fuc1Neu5Ac1
C-FS


5411


5412


5420


5421


5430


5431
2369.861
Hex5HexNAc4Fuc3Neu5Ac1
C/H-FS


5432
2660.957
Hex5HexNAc4Fuc3Neu5Ac2
C-FS


5432
2660.957
Hex5HexNAc4Fuc3Neu5Ac2
C-FS


5531
2572.941
Hex5HexNAc5Fuc3Neu5Ac1
C/H-FS


5541
2718.999
Hex5HexNAc5Fuc4Neu5Ac1
C-FS


5631
2776.020
Hex5HexNAc6Fuc3Neu5Ac1
C-FS


5650
2777.040
Hex5HexNAc6Fuc5
C-F


5700
2249.830
Hex5HexNAc7
C


5701
2540.926
Hex5HexNAc7Neu5Ac1
C-S


5702
2832.021
Hex5HexNAc7Neu5Ac2
C-S


5710
2395.888
Hex5HexNAc7Fuc1
C-F


5711
2686.984
Hex5HexNAc7Fuc1Neu5Ac1
C-FS


5712
2978.079
Hex5HexNAc7Fuc1Neu5Ac2
C-FS


5720
2541.946
Hex5HexNAc7Fuc2
C-F


5721
2833.042
Hex5HexNAc7Fuc2Neu5Ac1
C-FS


5730
2688.004
Hex5HexNAc7Fuc3
C-F


5730
2688.004
Hex5HexNAc7Fuc3
C-F


5731
2979.099
Hex5HexNAc7Fuc3Neu5Ac1
C-FS


6200


6200


6210
1542.544
GlcNAc2Man6Fuc1
HM-F


6300
1599.566
Hex6HexNAc3
H


6300


6301
1890.661
Hex6HexNAc3Neu5Ac1
H-S


6301


6310
1745.623
Hex6HexNAc3Fuc1
H-F


6310


6311
2036.719
Hex6HexNAc3Fuc1Neu5Ac1
H-FS


6311
2036.719
Hex6HexNAc3Fuc1Neu5Ac1
H-FS


6311


6320
1891.681
Hex6HexNAc3Fuc2
H-F


6400
1802.645
Hex6HexNAc4
H


6401
2093.740
Hex6HexNAc4Neu5Ac1
H-S


6401


6402
2384.836
Hex6HexNAc4Neu5Ac2
H-S


6410
1948.703
Hex6HexNAc4Fuc1
H-F


6410


6411
2239.798
Hex6HexNAc4Fuc1Neu5Ac1
H-FS


6421
2385.856
Hex6HexNAc4Fuc2Neu5Ac1
H-FS


6432
2823.009
Hex6HexNAc4Fuc3Neu5Ac2
H-FS


6500
2005.724
Hex6HexNAc5
C/H


6500


6501
2296.820
Hex6HexNAc5Neu5Ac1
C/H-S


6501


6502
2587.915
Hex6HexNAc5Neu5Ac2
C/H-S


6503
2879.011
Hex6HexNAc5Neu5Ac3
C-S


6510
2151.782
HexeHexNAc5Fuc1
C/H-F


6510


6511
2442.878
Hex6HexNAc5Fuc1Neu5Ac1
C/H-FS


6511
2442.878
Hex6HexNAc5Fuc1Neu5Ac1
C/H-FS


6511


6512
2733.973
Hex6HexNAc5Fuc1Neu5Ac2
C/H-FS


6513
3025.068
Hex6HexNAc5Fuc1Neu5Ac3
C-FS


6520


6521
2588.936
Hex6HexNAc5Fuc2Neu5Ac1
C/H-FS


6522
2880.031
Hex6HexNAc5Fuc2Neu5Ac2
C/H-FS


6530
2443.898
Hex6HexNAc5Fuc3
C/H-F


6530
2879.011
Hex6HexNAc5Neu5Ac3
C-S


6531
2734.993
Hex6HexNAc5Fuc3Neu5Ac1
C/H-FS


6532
3026.089
Hex6HexNAc5Fuc3Neu5Ac2
C/H-FS


6603
3082.090
Hex6HexNAc6Neu5Ac3
C-S


6623
3374.206
Hex6HexNAc6Fuc2Neu5Ac3
C-FS


6630
3082.090
Hex6HexNAc6Neu5Ac3
C-S


6631
2938.073
Hex6HexNAceFuc3Neu5Ac1
C-FS


6632
3229.168
Hex6HexNAc6Fuc3Neu5Ac2
C-FS


6641
3084.131
Hex6HexNAc6Fuc4Neu5Ac1
C-FS


6642
3375.226
Hex6HexNAc6Fuc4Neu5Ac2
C-FS


6652
3521.284
Hex6HexNAc6Fuc5Neu5Ac2
C-FS


6713
3431.227
Hex6HexNAc7Fuc1Neu5Ac3
C-FS


6731
3141.152
Hex6HexNAc7Fuc3Neu5Ac1
C-FS


6740
2996.115
Hex6HexNAc7Fuc4
C-F


7200
1558.539
GlcNAc2Man7
HM


7200


7200


7210
1704.597
GlcNAc2Man7Fuc1
HM-F


7400
1964.698
Hex7HexNAc4
H


7400


7401
2255.793
Hex7HexNAc4Neu5Ac1
H-S


7410
2110.756
Hex7HexNAc4Fuc1
H-F


7411
2401.851
Hex7HexNAc4Fuc1Neu5Ac1
H-FS


7412
2692.946
Hex7HexNAc4Fuc1Neu5Ac2
H-FS


7420
2256.814
Hex7HexNAc4Fuc2
H-F


7421
2547.909
Hex7HexNAc4Fuc2Neu5Ac1
H-FS


7430
2402.871
Hex7HexNAc4Fuc3
H-F


7431
2693.967
Hex7HexNAc4Fuc3Neu5Ac1
H-FS


7432
2985.062
Hex7HexNAc4Fuc3Neu5Ac2
H-FS


7500
2167.777
Hex7HexNAc5
H


7500
2167.777
Hex7HexNAc5
H


7511
2604.930
Hex7HexNAc5Fuc1Neu5Ac1
H-FS


7512
2896.026
Hex7HexNAc5Fuc1Neu5Ac2
H-FS


7601
2661.952
Hex7HexNAc6Neu5Ac1
C-S


7602
2953.047
Hex7HexNAc6Neu5Ac2
C-S


7610
2516.914
Hex7HexNAc6Fuc1
C-F


7610


7611
2808.010
Hex7HexNAc6Fuc1Neu5Ac1
C-FS


7611


7612
3099.105
Hex7HexNAc6Fuc1Neu5Ac2
C-FS


7613
3390.201
Hex7HexNAc6Fuc1Neu5Ac3
C-FS


7620
2662.972
Hex7HexNAc6Fuc2
C-F


7621
2954.068
Hex7HexNAc6Fuc2Neu5Ac1
C-FS


7640
2955.088
Hex7HexNAc6Fuc4
C-F


7713
3593.280
Hex7HexNAc7Fuc1Neu5Ac3
C-FS


7731
3303.205
Hex7HexNAc7Fuc3Neu5Ac1
C-FS


7740
3158.168
Hex7HexNAc7Fuc4
C-F


7741
3449.263
Hex7HexNAc7Fuc4Neu5Ac1
C-FS


8200
1720.592
GlcNAc2Man8
HM


8200

GlcNAc2Man8


8200


9200
1882.645
GlcNAc2Man9
HM


9200

GlcNAc2Man9


9200


9210
2028.702
GlcNAc2Man9Fuc1
HM-F


9210
2028.702
GlcNAc2Man9Fuc1
HM-F


10200
2044.697
GlcNAc2Man10
HM


10200


11200









Example 3—CA 125 ELISA

This Example refers to FIG. 20.


An protein CA 125 (cancer antigen 125) enzyme-linked immunosorbent assay (ELISA) was performed on patient samples. The patient pool consisted of n=187 women with malignant ovarian cancer (stages 1-4) and n=198 women with benign breast or pelvic masses, purchased from Indivumed, GmbH in March, 2018.


The results of the ELISA assay are shown in FIG. 20.


At a Cutoff=35; the ELISA assay was observed to diagnose malignant ovarian cancer at the following levels of accuracy, sensitivity and specificity:


Accuracy=85.2% Sensitivity=84.0% Specificity=86.4%


The samples had a positive predictive value at 20% Prevalence=60.7%


The samples had a negative predictive value at 20% Prevalence=95.6%


There are approximately 22,000 new cases of ovarian cancer in the United States every year, which stem from approximately 110,000 pelvic masses (at 20% prevalence). Though the CA-125 ELISA set forth in this Example showed higher than commonly reported values, with comparison to literature (which is more typically around 80% sensitive and 70% specific), as observed the CA-125 ELISA test would correctly identify 18,480 of the malignant cancer and 76,032 of the benign cancers. This results in 11,968 false positives and 3520 false negatives.


Example 4—Glycoproteomic Trained Model Test

This Example refers to FIG. 21.


A model trained using SEQ ID NOs.: 1-150 was to identify the probability that a given patient sample had ovarian cancer.


The patient pool consisted of n=187 women with malignant ovarian cancer (stages 1-4) and n=198 women with benign breast or pelvic masses, purchased from Indivumed, GmbH in March, 2018.


The results are shown in FIG. 21.


At a Cutoff=0.32; the model was observed to diagnose malignant ovarian cancer at the following levels of accuracy, sensitivity and specificity:


Accuracy=91.9% Sensitivity=91.4% Specificity=92.4%


The samples had a positive predictive value at 20% Prevalence=75.0%.


The samples had a negative predictive value at 20% Prevalence=97.7%.


There are approximately 22,000 new cases of ovarian cancer in the United States every year, which stem from approximately 110,000 pelvic masses (at 20% prevalence).


The glycoproteomic test set forth in this Example correctly identified 20,108 of the malignant cancers and 81,312 of the benign cancers. This results in 6,688 false positives and 1,892 false negatives.


Compared with CA-125 ELISA test in Example 3, herein, and in the United States alone, using the glycoproteomic test set forth, herein, in Example 4, results in 5,280 less incorrect cancer diagnoses per year, and 1,628 more correct diagnoses that would otherwise have been missed. These 6,908 additional correctly-diagnosed patients would all be triaged to the appropriate surgery and surgeon, where they would not have been with the CA-125 test. This results in significantly less stress on patients, as well as on the gynecologic oncologists required to perform surgeries on predicted malignancies.


The embodiments and examples described above are intended to be merely illustrative and non-limiting. Those skilled in the art will recognize or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials and procedures. All such equivalents are considered to be within the scope and are encompassed by the appended claims.

Claims
  • 1. A method of detecting one or more multiple-reaction-monitoring (MRM) transitions, comprising: obtaining, or having obtained, a biological sample from a patient, wherein the biological sample comprises one or more glycans or glycopeptides;digesting and/or fragmenting a glycopeptide in the sample; anddetecting a MRM transition selected from the group consisting of transitions 1-150.
  • 2. The method of claim 1, wherein the fragmenting a glycopeptide in the sample occurs after introducing the sample, or a portion thereof, into the mass spectrometer.
  • 3. The method of any one of claims 1-2, wherein the fragmenting a glycopeptide in the sample produces a peptide or glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof.
  • 4. The method of any one of claims 1-3, wherein the fragmenting a glycopeptide in the sample produces a peptide or glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.
  • 5. The method of any one of claims 1-4, wherein the MRM transition is selected from the transitions, or any combinations thereof, in any one of Tables 1-5.
  • 6. The method of any one of claims 1-5, wherein detecting a MRM transition selected from the group consisting of transitions 1-150 comprises detecting a MRM transition using a triple quadrupole (QQQ) mass spectrometer or a quadrupole time-of-flight (qTOF) mass spectrometer.
  • 7. The method of any one of claims 1-6, wherein the one or more glycopeptides comprises a peptide or glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof.
  • 8. The method of any one of claims 1-7, wherein the one or more glycopeptides comprises a peptide or glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.
  • 9. The method of any one of claims 1-8, comprising detecting one or more MRM transitions indicative of one or more glycans selected from the group consisting of glycan 3200, 3210, 3300, 3310, 3320, 3400, 3410, 3420, 3500, 3510, 3520, 3600, 3610, 3620, 3630, 3700, 3710, 3720, 3730, 3740, 4200, 4210, 4300, 4301, 4310, 4311, 4320, 4400, 4401, 4410, 4411, 4420, 4421, 4430, 4431, 4500, 4501, 4510, 4511, 4520, 4521, 4530, 4531, 4540, 4541, 4600, 4601, 4610, 4611, 4620, 4621, 4630, 4631, 4641, 4650, 4700, 4701, 4710, 4711, 4720, 4730, 5200, 5210, 5300, 5301, 5310, 5311, 5320, 5400, 5401, 5402, 5410, 5411, 5412, 5420, 5421, 5430, 5431, 5432, 5500, 5501, 5502, 5510, 5511, 5512, 5520, 5521, 5522, 5530, 5531, 5541, 5600, 5601, 5602, 5610, 5611, 5612, 5620, 5621, 5631, 5650, 5700, 5701, 5702, 5710, 5711, 5712, 5720, 5721, 5730, 5731, 6200, 6210, 6300, 6301, 6310, 6311, 6320, 6400, 6401, 6402, 6410, 6411, 6412, 6420, 6421, 6432, 6500, 6501, 6502, 6503, 6510, 6511, 6512, 6513, 6520, 6521, 6522, 6530, 6531, 6532, 6540, 6541, 6600, 6601, 6602, 6603, 6610, 6611, 6612, 6613, 6620, 6621, 6622, 6623, 6630, 6631, 6632, 6640, 6641, 6642, 6652, 6700, 6701, 6711, 6721, 6703, 6713, 6710, 6711, 6712, 6713, 6720, 6721, 6730, 6731, 6740, 7200, 7210, 7400, 7401, 7410, 7411, 7412, 7420, 7421, 7430, 7431, 7432, 7500, 7501, 7510, 7511, 7512, 7600, 7601, 7602, 7603, 7604, 7610, 7611, 7612, 7613, 7614, 7620, 7621, 7622, 7623, 7632, 7640, 7700, 7701, 7702, 7703, 7710, 7711, 7712, 7713, 7714, 7720, 7721, 7722, 7730, 7731, 7732, 7740, 7741, 7751, 8200, 9200, 9210, 10200, 11200, 12200, and combinations thereof.
  • 10. The method of claim 9, further comprising quantifying a first glycan and quantifying a second glycan; and further comprising comparing the quantification of the first glycan with the quantification of the second glycan.
  • 11. The method of claim 9 or 10, further comprising associating the detected glycan with a peptide residue site, whence the glycan was bonded.
  • 12. The method of any one of claims 1-11, comprising normalizing the amount of glycopeptide based on the amount of a peptide or glycopeptide consisting essentially of an amino acid having a SEQ ID. No: 1-262.
  • 13. A method for identifying a classification for a sample, the method comprising quantifying by mass spectroscopy (MS) one or more glycopeptides in a sample wherein the glycopeptides each, individually in each instance, comprises a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof; andinputting the quantification into a trained model to generate a output probability;determining if the output probability is above or below a threshold for a classification; andidentifying a classification for the sample based on whether the output probability is above or below a threshold for a classification.
  • 14. The method of claim 13, wherein the sample is a biological sample from a patient or individual having a disease or condition.
  • 15. The method of claim 14, wherein the patient has cancer, an autoimmune disease, or fibrosis.
  • 16. The method of claim 14, wherein the patient has ovarian cancer.
  • 17. The method of claim 14, wherein the individual has an aging condition.
  • 18. The method of claim 14, wherein the disease or condition is ovarian cancer.
  • 19. The method of any one of claims 13-18, wherein the MS is MRM-MS with a QQQ and/or qTOF mass spectrometer.
  • 20. The method of claim any one of claims 13-19, wherein the trained model was trained using a machine learning algorithm selected from the group consisting of a deep learning algorithm, a neural network algorithm, an artificial neural network algorithm, a supervised machine learning algorithm, a linear discriminant analysis algorithm, a quadratic discriminant analysis algorithm, a support vector machine algorithm, a linear basis function kernel support vector algorithm, a radial basis function kernel support vector algorithm, a random forest algorithm, a genetic algorithm, a nearest neighbor algorithm, k-nearest neighbors, a naive Bayes classifier algorithm, a logistic regression algorithm, or a combination thereof.
  • 21. The method of claim any one of claims 13-20, wherein the classification is a disease classification or a disease severity classification.
  • 22. The method of claim 21, wherein the classification is identified with greater than 80% confidence, greater than 85% confidence, greater than 90% confidence, greater than 95% confidence, greater than 99% confidence, or greater than 99.9999% confidence.
  • 23. The method of claim any one of claims 13-22, further comprising: quantifying by MS a first glycopeptide in a sample at a first time point;quantifying by MS a second glycopeptide in a sample at a second time point; andcomparing the quantification at the first time point with the quantification at the second time point.
  • 24. The method of claim 23, further comprising: quantifying by MS a third glycopeptide in a sample at a third time point;quantifying by MS a fourth glycopeptide in a sample at a fourth time point; andcomparing the quantification at the fourth time point with the quantification at the third time point.
  • 25. The method of any one of claims 13-24, further comprising monitoring the health status of a patient.
  • 26. The method of claim 25, wherein monitoring the health status of a patient comprises monitoring the onset and progression of disease in a patient with risk factors such as genetic mutations, as well as detecting cancer recurrence.
  • 27. The method of any one of claims 13-26, further comprising quantifying by MS an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.
  • 28. The method of any one of claims 13-26, further comprising quantifying by MS an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.
  • 29. The method of any one of claims 13-26, further comprising quantifying by MS one or more glycans selected from the group consisting of glycans 3200, 3210, 3300, 3310, 3320, 3400, 3410, 3420, 3500, 3510, 3520, 3600, 3610, 3620, 3630, 3700, 3710, 3720, 3730, 3740, 4200, 4210, 4300, 4301, 4310, 4311, 4320, 4400, 4401, 4410, 4411, 4420, 4421, 4430, 4431, 4500, 4501, 4510, 4511, 4520, 4521, 4530, 4531, 4540, 4541, 4600, 4601, 4610, 4611, 4620, 4621, 4630, 4631, 4641, 4650, 4700, 4701, 4710, 4711, 4720, 4730, 5200, 5210, 5300, 5301, 5310, 5311, 5320, 5400, 5401, 5402, 5410, 5411, 5412, 5420, 5421, 5430, 5431, 5432, 5500, 5501, 5502, 5510, 5511, 5512, 5520, 5521, 5522, 5530, 5531, 5541, 5600, 5601, 5602, 5610, 5611, 5612, 5620, 5621, 5631, 5650, 5700, 5701, 5702, 5710, 5711, 5712, 5720, 5721, 5730, 5731, 6200, 6210, 6300, 6301, 6310, 6311, 6320, 6400, 6401, 6402, 6410, 6411, 6412, 6420, 6421, 6432, 6500, 6501, 6502, 6503, 6510, 6511, 6512, 6513, 6520, 6521, 6522, 6530, 6531, 6532, 6540, 6541, 6600, 6601, 6602, 6603, 6610, 6611, 6612, 6613, 6620, 6621, 6622, 6623, 6630, 6631, 6632, 6640, 6641, 6642, 6652, 6700, 6701, 6711, 6721, 6703, 6713, 6710, 6711, 6712, 6713, 6720, 6721, 6730, 6731, 6740, 7200, 7210, 7400, 7401, 7410, 7411, 7412, 7420, 7421, 7430, 7431, 7432, 7500, 7501, 7510, 7511, 7512, 7600, 7601, 7602, 7603, 7604, 7610, 7611, 7612, 7613, 7614, 7620, 7621, 7622, 7623, 7632, 7640, 7700, 7701, 7702, 7703, 7710, 7711, 7712, 7713, 7714, 7720, 7721, 7722, 7730, 7731, 7732, 7740, 7741, 7751, 8200, 9200, 9210, 10200, 11200, 12200, and combinations thereof.
  • 30. The method of any one of claims 13-26, further comprising diagnosing a patient with a disease or condition based on the classification.
  • 31. The method of claim 42, further comprising diagnosing the patient as having ovarian cancer based on the classification.
  • 32. The method of any one of claims 13-26, further comprising treating the patient with a therapeutically effective amount of a therapeutic agent selected from the group consisting of a chemotherapeutic, an immunotherapy, a hormone therapy, a targeted therapy, and combinations thereof.
  • 33. A method for classifying a biological sample, comprising: obtaining a biological sample from a patient, wherein the biological sample comprises one or more glycopeptides;digesting and/or fragmenting one or more glycopeptides in the sample;detecting and quantifying at least one or more multiple-reaction-monitoring (MRM) transition selected from the group consisting of transitions 1-150; andinputting the quantification into a trained model to generate a output probability;determining if the output probability is above or below a threshold for a classification; andclassifying the biological sample based on whether the output probability is above or below a threshold for a classification.
  • 34. The method of claim 33, further comprising using a machine learning algorithm to train a model using the MRM transitions as inputs.
  • 35. A method for classifying a biological sample, comprising: obtaining a biological sample from a patient, wherein the biological sample comprises one or more glycopeptides;digesting and/or fragmenting one or more glycopeptides in the sample;detecting and quantifying at least one or more multiple-reaction-monitoring (MRM) transition associated with at least one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof; andinputting the quantification into a trained model to generate an output probability;determining if the output probability is above or below a threshold for a classification; andclassifying the biological sample based on whether the output probability is above or below a threshold for a classification.
  • 36. The method of claim 35, comprising detecting and quantifying at least one or more multiple-reaction-monitoring (MRM) transition associated with at least one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.
  • 37. The method of claim 35, comprising training a machine learning algorithm using the MRM transitions as inputs.
  • 38. A method for treating a patient having ovarian cancer; the method comprising: obtaining, or having obtained, a biological sample from the patient;digesting and/or fragmenting, or having digested or having fragmented, one or more glycopeptides in the sample; anddetecting and quantifying one or more multiple-reaction-monitoring (MRM) transitions selected from the group consisting of transitions 1-150;inputting the quantification into a trained model to generate an output probability;determining if the output probability is above or below a threshold for a classification; andclassifying the patient based on whether the output probability is above or below a threshold for a classification, wherein the classification is selected from the group consisting of: (A) a patient in need of a chemotherapeutic agent;(B) a patient in need of a immunotherapeutic agent;(C) a patient in need of hormone therapy;(D) a patient in need of a targeted therapeutic agent;(E) a patient in need of surgery;(F) a patient in need of neoadjuvant therapy;(G) a patient in need of chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof, before surgery;(H) a patient in need of chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof, after surgery;(I) or a combination thereof;administering a therapeutically effective amount of a therapeutic agent to the patient: wherein the therapeutic agent is selected from chemotherapy if classification A or I is determined;wherein the therapeutic agent is selected from immunotherapy if classification B or I is determined; orwherein the therapeutic agent is selected from hormone therapy if classification C or I is determined; orwherein the therapeutic agent is selected from targeted therapy if classification D or I is determinedwherein the therapeutic agent is selected from neoadjuvant therapy if classification F or I is determined;wherein the therapeutic agent is selected from chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof if classification G or I is determined; andwherein the therapeutic agent is selected from chemotherapeutic agent, immunotherapeutic agent, hormone therapy, targeted therapeutic agent, neoadjuvant therapy, or a combination thereof if classification H or I is determined.
  • 39. The method of claim 38, comprising conducting multiple-reaction-monitoring mass spectroscopy (MRM-MS) on the biological sample.
  • 40. The method of claim 38 or 39, comprising quantifying one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 and combinations thereof.
  • 41. The method of claim 38 or 39, comprising quantifying one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194 and combinations thereof.
  • 42. The method of any one of claims 38-41, comprising inputting the quantification of the amount of a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 into a machine learning algorithm to train a model.
  • 43. The method of any one of claims 38-42, comprising inputting the quantification of the amount of a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194 into a machine learning algorithm to train a model.
  • 44. The method of claim 43, wherein the machine learning algorithm is selected from the group consisting of a deep learning algorithm, a neural network algorithm, an artificial neural network algorithm, a supervised machine learning algorithm, a linear discriminant analysis algorithm, a quadratic discriminant analysis algorithm, a support vector machine algorithm, a linear basis function kernel support vector algorithm, a radial basis function kernel support vector algorithm, a random forest algorithm, a genetic algorithm, a nearest neighbor algorithm, k-nearest neighbors, a naive Bayes classifier algorithm, a logistic regression algorithm, or a combination thereof.
  • 45. The method of any one of claims 38-44, wherein the analyzing the transitions comprises selecting peaks and/or quantifying detected glycopeptide fragments with a machine learning algorithm.
  • 46. A method for training a machine learning algorithm, comprising: providing a first data set of MRM transition signals indicative of a sample comprising one or more glycopeptides, each glycopeptide, individually, consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262;providing a second data set of MRM transition signals indicative of a control sample; andcomparing the first data set with the second data set using a machine learning algorithm.
  • 47. The method of claim 46, wherein the sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 is a sample from a patient having ovarian cancer.
  • 48. The method of claim 46, wherein the sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194 is a sample from a patient having ovarian cancer.
  • 49. The method of claim 46, 47, or 48, wherein the control sample is a sample from a patient not having ovarian cancer.
  • 50. The method of any one of claims 46-49, wherein the sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-262 is a pooled sample from one or more patients having ovarian cancer.
  • 51. The method of any one of claims 49-49, wherein the sample comprising a glycopeptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194 is a pooled sample from one or more patients having ovarian cancer.
  • 52. The method of any one of claims 46-51, wherein the control sample is a pooled sample from one or more patients not having ovarian cancer.
  • 53. A method for diagnosing a patient having ovarian cancer; the method comprising: obtaining, or having obtained, a biological sample from the patient;performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect and quantify one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262; or to detect one or more MRM transitions selected from transitions 1-150;inputting the quantification of the detected glycopeptides or the MRM transitions into a trained model to generate an output probability,determining if the output probability is above or below a threshold for a classification; andidentifying a diagnostic classification for the patient based on whether the output probability is above or below a threshold for a classification; anddiagnosing the patient as having ovarian cancer based on the diagnostic classification.
  • 54. The method of claim 52, wherein the analyzing the detected glycopeptides comprises using a machine learning algorithm.
  • 55. The method of claim 52, comprising performing mass spectroscopy of the biological sample using MRM-MS with a QQQ and/or qTOF spectrometer to detect and quantify one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.
  • 56. A glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262, and combinations thereof.
  • 57. A glycopeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.
  • 58. A glycopeptide consisting essentially an amino acid sequence selected from the group consisting essentially of SEQ ID NOs:1-262, and combinations thereof.
  • 59. A glycopeptide consisting essentially an amino acid sequence selected from the group consisting essentially of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194, and combinations thereof.
  • 60. A kit comprising a glycopeptide standard, a buffer, and one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262.
  • 61. A kit comprising a glycopeptide standard, a buffer, and one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, 194.
  • 62. A computer-implemented method of training a neural network for detecting an MRM transition, comprising: collecting a set of mass spectroscopy spectra of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262;annotating the spectra including identifying at least one of a start, stop, maximum, or combination thereof, of a peak in a spectra to create an annotated set of mass spectroscopy spectra;creating a first training set comprising the collected set of mass spectroscopy spectra, the annotated set of mass spectroscopy spectra, and a second set of mass spectroscopy spectra of one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262;training the neural network in a first stage using the first training set;creating a second training set for a second stage of training comprising the first training set and mass spectroscopy spectra that are incorrectly detected as comprising one or more glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-262 after the first stage of training; andtraining the neural network in a second stage using the second training set.
  • 63. The method of claim 62, wherein the one or more glycopeptides are each individual in each instance glycopeptides consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 9, 12, 22, 24, 28, 32, 34, 35, 36, 37, 38, 53, 61, 65, 69, 82, 99, 104, 114, 115, 126, 128, 136, 146, 147, 150, 154, 177, 184, 190, and 194.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to, and the benefit, of U.S. Provisional Patent Application No. 62/800,323, filed Feb. 1, 2019, the entire contents of which are herein incorporated by reference in its entirety for all purposes.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2020/016286 1/31/2020 WO 00
Provisional Applications (1)
Number Date Country
62800323 Feb 2019 US